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Objective of the thesis 
The primary objective of this thesis is to explore the function of acetylation of SRSF5 
protein by characterizing the phenotype of SRSF5 proteins with mutated acetylation site. 
The hypothesis to be tested is that the properties of amino acid side chain at the site of 
acetylation influence interaction of SRSF5 with RNA. 
Abstract 
Acetylation is emerging as an important posttranslational modification, which is found in 
thousands of proteins in eukaryotes, as well as prokaryotes. Global proteomic studies 
implicated acetylation in regulation of various processes like metabolism, gene expression, 
cell cycle or aging to name a few. In this work I set out to investigate the role of acetylation 
of a splicing regulatory protein SRSF5 by creating mutations in its acetylation site. I tested 
the hypothesis that acetylation influences SRSF5 interaction with RNA. I expressed 
acetylation-mimicking (Q) or non-acetylable (R) mutant of SRSF5 in HeLa cells and measured 
their interaction with RNA by RNA immunoprecipitation or in vitro by fluorescence 
anisotropy. Both approaches agreed that mutants interact with RNA less than the wild type 
protein and Q mutant bound RNA weaker than R mutant. 
I did not detect further difference in localization or dynamics among the proteins in vivo, 
which suggests that difference caused by weakened interaction of mutants with RNA was 
outweighed by other factors influencing SRSF5 behaviour, probably protein-protein 
interactions. I also found out that mutant SRSF5 proteins do not have a dominant effect on 
splicing of fibronectin alternative EDB exon. 
The data obtained give an indirect evidence for the hypothesis that acetylation influences 
binding of SRSF5 to RNA. The low RNA affinity of acetylation-mimicking mutant suggests that 
acetylation reduces SRSF5 binding to RNA. This finding might be intersting, because there is 
a lot of other proteins with reported acetylation in RNA-binding domain implicating 
acetylation in regulation of RNA binding and consequently in regulation of pre-mRNA 
splicing. 






Acetylace je významná posttranslační modifikace, která byla nalezena u několika tisíc 
proteinů jak u eukaryot, tak u prokaryot. Globální proteomické studie odhalily, že acetylace 
reguluje mnoho procesů např. metabolizmus, genovou expresi, buněčný cyklus, stárnutí a 
mnohé další. V této práci jsem studoval roli acetylace sestřihového faktoru SRSF5 pomocí 
mutací v jeho acetylačním místě. Testoval jsem hypotézu, že acetylace ovlivňuje vazbu SRSF5 
na RNA. V HeLa buňkách jsem exprimoval mutované proteiny SRSF5, jednak mutanta 
napodobujícího acetylovanou formu (Q) a také neacetylovatelného mutanta (R) a zjišťoval 
jsem jejich interakci s RNA pomocí RNA imunoprecipitace a také in vitro měřením 
fluorescenční anizotropie. Výsledky obou metod se shodly na tom, že oba mutanty interagují 
s RNA méně než přirozená forma proteinu a Q mutant se vázal na RNA slaběji než R mutant. 
Mutanty se naopak od přirozené formy SRSF5 nelišily v lokalizaci a dynamice v buňce. 
Rozdíly ve vazbě na RNA byly pravděpodobně překryty dalšími faktory, které ovlivňují 
chování SRSF5, nejspíše protein-proteinovými interakcemi. Mutantní SRSF5 také neměly 
dominantní efekt na sestřih alternativního EDB exonu fibronektinu. 
Získané výsledky poskytují nepřímý důkaz pro hypotézu, že acetylace má vliv na vazbu 
SRSF5 na RNA. Mutant napodobující acetylovanou formu proteinu se vázal na RNA nejméně, 
což naznačuje, že acetylace snižuje interakci SRSF5 s RNA. Toto zjištění může být zajímavé i 
obecněji, jelikož u mnoha dalších proteinů byla také zjištěna acetylace v RNA vazebné 
doméně, což činí z acetylace nového hráče v regulaci RNA-proteinových interakcí a potažmo i 




Table of contents 
 
Introduction ................................................................................................................. 7 
Lysine acetylation .............................................................................................................. 7 
Histone acetyl transferases (HATs) and histone deacetylases (HDACs) ........................ 8 
Lessons learned from global acetylation studies ......................................................... 13 
Regulation of cellular metabolism by acetylation ....................................................... 16 
Mechanisms of influence of acetylation on protein function ..................................... 19 
Acetylation alters RNA-protein interaction ................................................................. 22 
SR proteins ....................................................................................................................... 24 
Binding of SR proteins to RNA ...................................................................................... 26 
Acetylation of SR proteins and its function.................................................................. 29 
Materials and methods............................................................................................... 31  
Results ........................................................................................................................38 
SRSF5 localisation ............................................................................................................ 39 
Acetylation and phosphorylation of SRSF5 ...................................................................... 40 
Dynamics of SRSF5 proteins in vivo ................................................................................. 41 
Quantification of SRSF5 interaction with RNA by RNA immunoprecipitation (RIP) ........ 43 
GST-SRSF5 protein purification and buffer optimization ................................................ 45 
Quantification of SRSF5 interaction with RNA in vitro .................................................... 46 








List of abbreviations 
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siRNA small interfering RNA 
snRNP small nuclear ribonucleoprotein 
SR proteins serine/arginine-rich proteins 
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TCA cycle tricarboxylic acid cycle 
TF transcription factor 
TSA trichostatin A 








The acetylation of proteins was discovered almost fifty years ago as a posttranslational 
modification of histones influencing gene expression (Allfrey et al., 1964) and for a long time 
it was studied exclusively in this respect. Later on, more targets of acetylation was reported, 
such as tubulin (L'Hernault and Rosenbaum, 1985) and p53 (Gu and Roeder, 1997), but 
acetylation was not systematically studied. All these cases fall into the category of ε-N-lysine 
acetylation (AcK) which I will review in this introduction. I will not focus on structurally 
similar, but functionally distinct, α-N-terminal acetylation, which is actually the most 
frequent protein acetylation present in 80% of human proteins and among other functions 
prevents proteins from entering the secretory pathway, regulates protein-protein 
interaction and influences their stability (Arnesen, 2011). When people discuss the influence 
of acetylation on protein function, they often mention that acetylation neutralizes positive 
charge on lysine residues, but we should not forget that acetylation also changes the overall 
size of the side chain, its hydrophobicity and potential to form hydrogen bonds. 
The view of AcK has changed in last few years and attention is turning from histones to 
other acetylated proteins as well. For a long time, research on protein acetylation was 
limited by lack of adequate methods and only individual cases of acetylation were studied. 
Recently the development in the field of mass spectrometry and first antibodies reactive 
against acetylated lysine allowed researchers to uncover the true scope of lysine acetylation 
(Choudhary et al., 2009; Kim et al., 2006). The current view is that acetylation is of equal 
importance as phosphorylation, regulating many cellular processes, such as gene expression, 
cell cycle, metabolism, actin cytoskeleton dynamics or aging (Norris et al., 2009). It is 
widespread and evolutionarily conserved. Many AcK appear in prokaryotes as well, where 
they regulate mainly metabolism, flagellar motion, translation but also other processes 
(Jones and O'Connor, 2011).  
The research on AcK led to many medically relevant discoveries, for example some 
inhibitors of lysine deacetylating enzymes are in use or in clinical trials for treatment of 
cancer, neurodegenerative diseases or as anti-inflammatory drugs. They can be also used for 
improving the efficiency of induction of pluripotent stem cells (Huangfu et al., 2008). The 
mechanism of action of lysine deacetylase inhibitors is still unclear, probably different subset 
of acetylation sites in the cell is influenced in each application. 
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Histone acetyl transferases (HATs) and histone deacetylases (HDACs) 
The acetylation in the cell is maintained in equilibrium by opposing activities of HATs and 
HDACs. The histone in their name is given by historical circumstances of their discovery. 
Histones were the first discovered substrate but now we know many non-histone porteins 
that are targets of HATs and HDACs. Relatively small number of HATs (30) and HDACs (18) 
regulate thousands of acetylation sites, which makes AcK different from phosphorylation 
that is carried out by 500 kinases and about 150 phosphatases. Similarly the ubiquitination is 
carried out by 1000 E3 ligases and 80 deubiquitinylating enzymes (Guan and Xiong, 2011). So 
what is the determinant of acetylation specificity? The sequence around the acetylation 
sites, though being somewhat conserved, cannot itself explain acetylation specificity. The 
major determinant of AcK is still matter of debate, protein-protein interactions definitely 
play an important role.  
HATs occur usually in macromolecular complexes and we can divide them into three 
families CBP/p300, MYST  and GNAT. They have multiple subunits and the function of the 
catalytically active subunit is regulated in terms of activity and substrate specificity by 
composition of the whole complex. For this reason, in vitro experiments with purified HATs 
often give misleading results. HAT complexes contain many chromatin-binding domains such 
as bromodomain that binds acetylated lysines and chromodomain, Tudor domain, WD40 
repeats and PHD fingers that all bind various methylated lysines. HATs use acetyl-CoA as a 
source of acetyl group, which links their activity to the metabolic state of the cell. 
CBP/p300 family of proteins were discovered as coactivators of transcription, that are 
recruited by transcription factors (TFs) to transcription units. The acetyltransferase activity, 
which is at the core of their coactivator function, was discovered later. Currently there are 
over 40 TFs known to interact with p300 or CBP (CREB binding protein), notably p53, nuclear 
hormone receptors, Fos, Jun, STAT or Smad (Chen and Li, 2011). CBP and p300 are two 
highly homologous proteins with mostly overlapping functions but a few specific ones as 
well (Kalkhoven, 2004). These two proteins are large and possess various domains like HAT, 
Bromodomain and several transcription factor-interacting domains KIX, C/H1, 2 and 3. The 
pivotal substrates of p300 are histones and transcription factors. Besides its enzymatic 
function p300 serves as a scaffold for transcription factors or as a  bridge for TFs with the 
general transcription machinery (Chen and Li, 2011). p300 is activated by autoacetylation 
and also by phosphorylation mediated by cyclin-dependent kinases or by Akt. 
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Phosphorylation in general increases resistance of p300 to proteasomal degradation. The 
level of p300 in the cell is often crucial for transcription regulation, because individual 
transcription units compete for a limited pool of p300. Activating role of p300 is also 
regulated by its export to cytoplasm, where it has another unrelated function as a p53 E4 
ubiquitin ligase. It has a ubiquitin ligase domain on N-terminus that is active only in 
cytoplasm. This destabilizing effect on p53 in the cytoplasm is interesting, because 
acetylation of p53 in the nucleus has the opposite effect and stabilizes p53 (Chen and Li, 
2011). p300 participates also in other processes that require chromatin remodeling, such 
as DNA replication and DNA repair. 
CBP and p300 are essential and mutations or other inactivation of CBP gene that lead to 
reduction of active protein by 50 % cause Rubinstein-Taybi syndrome (RTS), which manifests 
itself as developmental abnormalities, mental retardation and increased incidence of 
cancers. The mutations causing RTS are mostly found in the acetyltransferase domain, but a 
mutation in bromodomain was also reported (Kalkhoven, 2004). The role of CBP and p300 in 
cancer is not resolved, in some cases it behaves as tumor suppressor. It is mutated in some 
cancers of epithelial origin but larger studies of tumors and cancer cell lines failed to 
discover frequent mutations in CBP. CBP and p300 play a distinct role in acute myeloid 
leukemia. Often there appear translocations causing fusion of p300 or CBP with MLL or MOZ 
proteins producing a protein with altered HAT activity (Kalkhoven, 2004). 
The HATs from MYST family are phylogenetically widespread predominantly nuclear 
proteins that regulate most processes localized to this cellular compartment. The most 
studied member of the family, Tip60 acetyltransferase, is an important player in 
transcription regulation. It acetylates both histones and transcription factors such as p53 or 
c-Myc. Tip60 also promotes DNA damage response to double-strand breaks by acetylating 
histones in the site of break and by activating the ATM kinase (Sapountzi and Cote, 2011). 
The GNAT family contains Gcn5, the first HAT discovered, PCAF (p300/CBP-associated 
factor) and many related proteins. They function similarly to CBP/p300 as transcription 
coactivators acetylating histones and nonhistone proteins. Gcn5 is essential for embryonic 
development in mice and Drosophila unlike PCAF. PCAF knockout mice develop normally but 
have elevated levels of Gcn5, which suggests that Gcn5 is able to replace PCAF in most of its 
functions. Gcn5 like other HATs participates in several well known macromolecular 
complexes. In yeast it is the large SAGA complex and smaller ADA complex, in humans its 
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SAGA homologs STAGA and TFTC and ADA homolog ATAC. Similar complexes were found in 
Drosophila as well. Besides the HAT domain, PCAF contains also E3 ubiquitin ligase domain 
and ubiquitinates p53 (Nagy and Tora, 2007). 
In mammals there are fivevclasses of HDACs with total 18 members, which rises 
interesting questions about their specificity and redundancy. Class I, IIa, IIb and IV are Zn2+ 
dependent and class III, sirtuins, are NAD+ dependent. Class I HDACs are expressed 
ubiquitously and they are components of various corepressor complexes in the nucleus such 
as NuRD or Polycomb repressive complexes so their major substrates are acetylated histone 
N-termini and their role is silencing gene expression (there are also reported cases of gene 
activation (Haberland et al., 2009)). Mouse knockouts of members of all classes, except for 
class IIa, are often lethal embryonically or around birth suggesting important functions for 
HDACs in development (Haberland et al., 2009). The severe phenotype might also be caused 
by disintegration of complexes HDACs would normally be found in.  
Class I HDACs are the usual target of HDAC inhibitors, unlike class IIa HDACs that are 
resistant to most inhibitors in use (Delcuve et al., 2012). A recent study (Bantscheff et al., 
2011) put most of the data about specificity of HDAC inhibitors in question, because instead 
of using purified HDACs they examined HDAC inhibition within the macromolecualr 
complexes where they naturally occur. The inhibition of particular HDAC proved to be 
dependent not only on the class of HDAC but also on the complex it was part of. There is a  
striking difference between mostly lethal HDAC knockouts and mild effect of chemical HDAC 
inhibition. It probably arises from disruption of protein complexes containing HDACs that are 
not properly formed in the knockouts (Haberland et al., 2009). Most inhibitors in use are 
broad-spectrum and affect all but class IIa HDACs and sirtuins. Global inhibition of HDACs has 
often surprisingly specific and beneficial effect in treatment of many diseases (Table 1). The 
utility of HDAC inhibitors against so many miscellaneous diseases reflects the ubiquitous 
cellular regulation by protein acetylation. First at the level of transcription and also in 




Table 1: Diseases treated with HDAC inhibitors and their proposed mechanism of action (Haberland et al., 
2009). 
Class II HDACs are both nuclear and cytoplasmic and their export from the nucleus is 
activated by phosphorylation and following 14-3-3 protein binding. Class IIa proteins are 
expressed tissue-specifically and they are not themselves catalytically active, but they form a 
heterodimer with class I HDACs. Knockout mice for class IIa HDACs are mostly viable, 
probably due to redundancy among them, even though the pattern of their expression is 
diverse. Class IIb HDACs target other proteins rather than histones mostly in the cytoplasm 
and cytoplasmatic membrane. One member of the family, HDAC6, is the deacetylase of α-
tubulin and of diverse proteins regulating the actin cytoskeleton. So HDAC6 is a potent 
regulator of cell motility, which makes it an interesting anticancer drug target.  Another well 
known target of HDAC6 is HSP90. HDAC6 is also associated with aggresome, a proteinaceous 
inclusion body that forms when a cell is overwhelmed by misfolded proteins implicating a 
role for HDAC6 in neurodegenerative disease. Mouse knockout of HDAC6 has surprisingly 
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mild phenotype, only highly acetylated microtubules, which probably stems from the 
redundancy with the other member of class IIb, HDAC10 (Delcuve et al., 2012). The only 
class IV HDAC, HDAC11, is not very well explored.  
Sirtuins (class III HDACs) are a family of proteins conserved from prokaryotes to 
mammals. They were first discovered in yeast as regulators of heterochromatin silencing, 
but they gained attention because they also prolonged yeast lifespan (Kaeberlein et al., 
1999). Soon their main function as deacetylases was discovered (Imai et al., 2000). Unlike 
other HDACs that simply hydrolyze acetylated lysine, sirtuins use NAD+ (not NADH or NADP+) 
in the deacetylation reaction. They cleave it yielding lysine, nicotinamide and 2′-O-acetyl-
ADP-ribose. The product of this reaction, nicotinamide, is an inhibitor of sirtuin activity. 
Sirtuins are dependent on the cellular levels of NAD+ or NAD+/NADH ratio, which predestines 
them to be sensors of cellular metabolic state (Houtkooper et al., 2012). Sirtuins have also 
other enzymatic functions related to acetylation such as demalonylation and desuccinylation 
and ADP-ribosylation, which arises from the NAD+ cleavage. 
The best explored are nuclear sirtuin SIRT1 and mitochondrial SIRT3. From studies on 
transgenic mice it emerged that SIRT1 is one of the factors that mediate the benefitial 
effects of calorie restriction regimen, such as reduction of age-related health problems. 
SIRT1 improves the sensitivity of body to insulin and also insulin secretion in pancreas by 
deacetylating histones and other proteins like transcription factors. It is a promising drug 
target for treatment of type-2 diabetes (Houtkooper et al., 2012). SIRT3 is the main 
mitochondrial deacetylase regulating many mitochondrial metabolic enzymes. It is also 
important during calorie restriction and other stresses, where it reduces ROS production by 
activating SOD2 and through other mechanisms.  
 A lively area of research is the role of sirtuins in longevity. As calorie restriction regimen 
increases longevity in wide spectrum of species, it was speculated that sirtuins as one of the 
enzymes activated by calorie restriction could themselves be longevity factors. But besides 
yeast, the role of sirtuins in longevity shown in the initial studies is now questioned by newer 
data from Caenorhabditis elegans, Drosophila melanogaster and mice overexpressing SIRT1 
showing none or negligible extension of lifespan (Houtkooper et al., 2012). But other model 
emerges. Sirtuins do not extend lifespan, but rather healthspan by their favourable effect on 
age-related metabolic diseases and in situations of metabolic stress like high fat diet 
demonstrated in SIRT1 knockin mice (Houtkooper et al., 2012). Most of the studies in this 
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field were done on SIRT1 but other sirtuins, which are the target of intensive research now, 
might still regulate longevity. 
Activation of benefitial effects of sirtuins by rather uncomfortable calorie restriction led 
to the thought that instead, small molecule agonists of SIRT1 could be used to improve the 
age-related or unhealthy diet-triggered metabolic complications in humans. The first 
discovered SIRT1 activator was a plant polyphenolic compound resveratrol, which mimicked 
the effect of calorie restriction and extended the lifespan of yeasts (Howitz et al., 2003). 
Resveratrol activates SIRT1 in mice and humans as well. Although it turned out, that SIRT1 is 
probably not a direct target of resveratrol. It enhances mitochondrial function and protects 
mice againts diet-induced obesity. It also extends their lifespan, when they are metabolically 
stressed by high fat diet. Artificial agonists of SIRT1 were also prepared, the most potent 
one, SRT1720, has similarly beneficial effects as resveratrol (Houtkooper et al., 2012).  
 
Lessons learned from global acetylation studies 
Kim and colleagues published the first global acetylation study in 2006 where they 
identified 388 acetylation sites in 195 proteins (Kim et al., 2006) and by which they more 
than doubled the number of acetylated proteins known at that time. This study was 
technically feasible because they used a newly prepared anti-acetylated lysine antibody for 
initial enrichment of trypsin-digested peptides. Some kind of enrichment is necessary in such 
a study and is a common approach also in phosphoproteomics. As the material for analysis 
they used HeLa cells and mouse mitochondria. Their most important finding was probably 
the unexpected discovery of widespread AcK in mitochondria, which indicates a connection 
of acetylation to energy metabolism. I`ll discuss that in a separate section later. Among the 
acetylated proteins were also chaperones, RNA splicing and translation factors and many 
regulators of actin cytoskeleton and also actin itself.  
They tested the role of acetylation on actin cytoskeleton by agonists and antagonists of 
histone deacetylases and found that agonists (causing low acetylation) destabilized and 
antagonists (causing high acetylation) stabilized filamentous actin, which resulted in 
formation of more stress fibers. This is in concordance with other observation about 
acetylation-mimicking mutation (lysine to glutamine) in regulator of Rho GTPases, RhoGDI, 
that caused stress fiber formation unlike lysine mutation to arginine, which mimics 
nonacetylated lysine and did not significantly change actin cytoskeleton. 
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 The number of identified acetylation sites allowed for the first search of acetylation 
motive in the surrounding protein sequence. It was different in nuclear and cytoplasmic or 
mitochondrial proteins, which probably reflects distinct acetylating enzymes acting in 
different cellular compartments. As for the secondary structures, AcK is found more often in 
structured regions (helices) compared to nonacetylated lysines and less frequently in 
unstructured regions than the nonacetylated lysines (histones being an exception). This 
makes them different from phosphorylations, which correlate with unstructured regions. 
The next study confirmed the findings of Kim and colleagues and broadened them 
significantly (Choudhary et al., 2009). After the enrichment for acetylated peptides they 
employed further fractionation which helped to overcome the problem that the sample 
after affinity step is dominated by a few most abundant acetylated peptides. The list of 
acetylation sites was expanded to 3600 in 1750 proteins from three different human cancer 
cell lines. The acetylomes of these three cell lines significantly overlapped indicating that the 
study got close to mapping the whole human acetylome. Though more acetylations might 
still be found under different growth conditions and in different cell lines or tissues. Authors 
gained many important insights from global analysis of the human acetylome. The amount 
of data collected in this study also allows for computational prediction of acetylation sites 
(Wang et al., 2012). 
The acetylated proteins were found to be more evolutionarily conserved when compared 
to the whole proteome. Acetylation was overrepresented in several Pfam protein domains. 
Specifically nuclear domains, such as RNA binding motives and helicases. On the other hand 
the most underrepresented domains were membrane seven helix receptors, EGF-like and 
peptidase domains. AcK was also significantly enriched in proteins that are part of big 
protein complexes such as HAT complexes or chromatin-remodeling complexes. Further 
analysis unexpectedly revealed clusters of closely interacting acetylated proteins taking part 
in various cellular processes such as RNA splicing, DNA repair, cell cycle, cytoskeleton 
reorganization, protein folding, nuclear transport or within the ribosome. The high 
acetylation of RNA binding motives and overall high acetylation of splicing proteins reported 
in this study were the primary motivation for starting my project. 
They also quantitatively analyzed (by SILAC) global effect of two HDAC inhibitors. SAHA, a 
broad spectrum inhibitor of HDACs (except for sirtuins) and MS-275, which is specific for 
class I HDACs. Both inhibitors were surprisingly specific and increased acetylation more than 
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two fold at only 10% of acetylation sites. SAHA was more potent inducer of lysine 
acetylation. As expected, the mitochondrial acetylation was not influenced. The set of 
influenced sites by these two inhibitors overlapped (differently for particular cell line) at 
around 50%. At some well known acetylated proteins each inhibitor had distinct effect. For 
example SAHA upregulated acetylation of HSP90 unlike MS-275 and MS-275 increased 
acetylation of p53 and SAHA had no effect. Such specificity of inhibitors, which have also 
different mechanism of action, explains their distinct effects in research and in clinical 
applications. 
Acetylation sites or events can be divided into two groups. In the first category, there are 
proteins with only one or very few exceptionally specific acetylation sites, but they are 
sufficient for altering the protein properties and serve as a switch. Secondly, some proteins 
have a patch of more lysine residues that can be all acetylated with the same outcome. The 
acetylations are interchangeable, what matters is the overall charge of that protein segment. 
It was noticed already before the study of Choudhary and colleagues was published (Yang 
and Seto, 2008). 
Other study focused on acetylation of proteins in mitochondria and cytoplasm in human 
liver (Zhao et al., 2010). They described 703 previously unknown acetylated proteins. Their 
dataset included 70% of acetylated proteins discovered by Kim and colleagues in mouse liver 
but only 14%  of acetylated proteins from human cancer cells reported by Choudhary and 
collegues. It indicates that acetylation is conserved in the same cell type across species but 
various cell types in one body can have completely different acetylation patterns. They 
focused on metabolic enzymes because they found acetylation in virtually every enzyme 
from glycolysis, TCA cycle, gluconeogenesis, glycogen and fatty acid metabolism or urea 
cycle.  
They mapped in detail the influence of nutrients and HDAC inhibitors on acetylation of 
several selected enzymes and how acetylation affects their activity. They used Chang human 
liver cells expressing FLAG-tagged proteins for immunoprecipitation, and iTRAQ isobaric tags 
for MS quantification of acetylated peptides. The EHHADH enzyme from fatty acid 
metabolism was positively regulated by acetylation. Acetylation of EHHADH increased after 
treatment with HDAC inhibitors nicotinamide and TSA from 40% to 70% and activity of the 
enzyme doubled. Activity and acetylation of EHHADH was also inceased by additon of fatty 
acids to the culture medium implicating acetylation in physiological regulation of EHHADH 
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function. The acetylation of TCA cycle enzyme malate dehydrogenase (MDH) increased from 
30% to 70% after treatment of cells with nicotinamide and TSA and activity of the enzyme 
doubled. Incubation of cells in high glucose conditions increased again the acetylation and 
activity of MDH. Consistently in vitro deacetylation of MDH decreased its activity and MDH 
mutant with acetylated lysines changed to arginines did not respond to either HDAC 
inhibitors or increased glucose by increased enzymatic activity.  
The urea cycle enzyme, argininosuccinate lyase (ASL), was negatively regulated by 
acetylation. The HDAC inhibitors increased its acetylation, which lowered ASL enzymatic 
activity. Growing cells in high concentration of amino acids decreased the acetylation and 
increased activity of ASL. And in vitro deacetylation of ASL increased its activity. The urea 
cycle is connected to TCA cycle and gluconeogenesis because in low glucose conditions, the 
cells use fumarate from the urea cycle as an energy source and for gluconeogenesis. So in 
low glucose conditions urea cycle enzymes are more active than in high glucose conditions 
and indeed in high glucose conditions ASL was more acetylated and less active. It shows that 
acetylation can be a signal, which connects more metabolic pathways together.  
In the last case it was shown that acetylation destabilizes gluconeogenic enzyme PEP 
carboxykinase (PEPCK) in high glucose conditions, when gluconeogenesis is not required.  In 
high glucose conditions PEPCK was more acetylated, but the overall amount of protein 
dropped. Treatment with HDAC inhibitors had similar effect. On the contrary PEPCK was 
stable in glucose-free medium. The PEPCK mutant with acetylated lysines swapped to 
arginines was also more stable than the wild type. 
All these results show that a substantial fraction of an enzyme in the cell can be 
acetylated and this acetylation changes dynamically in response to nutrient availability and 
metabolic condition of cells. The signal relayed by acetylation coordinates different 
metabolic pathways in response to changing conditions. I will expand these ideas in the next 
section. 
 
Regulation of cellular metabolism by acetylation 
Acetylation is intimately linked to energy metabolism because the donor of acetyl group 
in the reaction is acetyl-CoA. Deacetylation by sirtuins as already mentioned requires 
oxidized NAD. In the most general view, we can say that acetylation dominates when 
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nutrients are abundant, acetyl-CoA is high, NAD+ level is low thus SIRT activity is low, which 
leads to high acetylation. During starvation it is vice versa and deacetylation steps in. 
AcK is not the only posttranslational modification connected with metabolism. Basically 
all PTMs are generated from metabolites and therefore might be sensitive to nutrient levels. 
There is evidence supporting this view  at least for glycosylation and acetylation (Wellen and 
Thompson, 2012). This is likely also for modifications analogous to acetylation like 
butyrylation, propionylation and succinylation, which were found in past years (Garrity et al., 
2007; Zhang et al., 2009; Zhang et al., 2011). They all have in common that they can be 
found in cells as CoA derivatives. 
AcK is involved in regulation of metabolism in all domains of life. Besides the mouse and 
human examples (Choudhary et al., 2009; Kim et al., 2006; Zhao et al., 2010) there were 
reports describing frequent acetylation of metabolic enzymes in Escherichia coli (Yu et al., 
2008; Zhang et al., 2009) and Salmonella enterica (Wang et al., 2010) and there are few 
reported acetylated proteins in Archaea as well (Jones and O'Connor, 2011), probably many 
more would be found if someone performed a comprehensive survey. Yu and colleagues 
discovered 85 acetylated proteins in E.coli most of which were metabolic enzymes or 
proteins involved in proteosynthesis. The majority of proteins were acetylated in stationary 
phase and deacetylated in exponential phase suggesting a regulatory role for acetylation in 
bacterial physiology (Yu et al., 2008).  
The second study on E. coli (Zhang et al., 2009) acquired AcK dataset of similar size but 
not much overlapping with the previous study, which probably reflects undersampling and 
difference in bacterial strains and growth conditions between these two studies. Zhang and 
colleagues came to similar conclusions and furthermore they found also increased AcK in 
stress conditions and in stress response proteins. They also highlighted that lots of 
acetylations are conserved from prokaryotes to mammals (Zhang et al., 2009). 
The study on Salmonella revealed 191 acetylated proteins out of which one half were 
metabolic enzymes of assorted pathways. 90% of enzymes in basic metabolic pathways like 
glycolysis and TCA cycle were acetylated (Wang et al., 2010). They grew cells in fermenting 
conditions with glucose as carbon source (high glycolysis) or in oxidative conditions with 
citrate (high gluconeogenesis). Higher AcK was found in bacteria growing on glucose and it 
was demonstrated that acetylation stimulates glycolysis and inhibits gluconeogenesis. The 
authors exploited an advantage of Salmonella having only one major HAT and HDAC (NAD+ 
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dependent) so deletion mutants with much reduced HAT and HDAC activity could be easily 
created. They prepared those mutants and as expected the deacetylase mutant had more 
acetylated proteins and the acetyltransferase mutant had lower overall acetylation. When 
they compared the growth rate of the deacetylase mutant on glucose with the wild type, it 
grew faster. On citrate it grew slower. The experiments with acetyltransferase mutant gave 
the opposite results. It is in agreement with the model that acetylation stimulates glycolysis 
and inhibits gluconeogenesis.  
This hypothesis was supported also by close examination of GAPDH, an enzyme of both 
glycolysis and gluconeogenesis. When this enzyme was acetylated, it favoured the forward 
glycolytic reaction and when it was deacetylated, it was more effective at the reverse 
gluconeogenic reaction (Wang et al., 2010). These results were also confirmed by feeding 
the bacteria with 13C glucose or citrate and measurements of metabolite levels in vivo. For 
example when grown on glucose, the deacetylase mutant had two times bigger ratio of 
glycolysis/gluconeogenesis intermediates compared to the acetyltransferase mutant (Wang 
et al., 2010). The major contribution of this study is characterizing how AcK regulates 
activities of metabolic enzymes and how it influences flow of carbon through metabolic 
pathways. Most of the findings might be valid for eukaryotes as well, e.g., human GAPDH is 
acetylated as well. It remains to be tested if the acetylation influences the enzyme the same 
way as in Salmonella. 
The requirement of acetylation for glycolysis could be potentially used against various 
types of cancers, because they are dependent mostly on glycolysis and subsequent 
fermentintation to lactate. Their rate of glycolysis is hundred times higher than that of 
healthy tissues (Kim and Dang, 2006), so for example HAT inhibitors or sirtuin agonists could 
considerably inhibit tumor growth. 
The situation of acetylation in mitochondria is more ambiguous. Elevated fatty acid 
oxidation in low nutrient situations would increase acetyl-CoA and therefore increase 
acetylation, on the other hand nutrient shortage activates mitochondrial SIRT3, which 
deacetylates and activates oxidative enzymes and scavengers of reactive oxygen species 
(Guarente, 2011). Activation of these enzymes accounts for the therapeutic effect of sirtuins 
on age-related diseases. The change in mitochondrial acetylation during calorie restriction is 
tissue-specific as was shown in mice (Schwer et al., 2009). In liver mitochondria, AcK was 
increased on 72 enzymes. In brown fat calorie restriction had the opposite effect and 
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decreased mitochondrial acetylation. In other tissues like brain, kidney or heart AcK did not 
change (Schwer et al., 2009). It is not surprising for a multicellular organism, because the 
liver and fat are professional metabolizing tissues that sense, store and metabolize nutrients 
to provide stable supply of glucose and lipids into the bloodstream for the rest of the body. 
Further evidence for close relationship of acetylation and metabolism, apart from the 
metabolic enzymes, is the regulatory role of acetylation in insulin-like growth factor receptor 
signaling. Acetylation of PTEN inhibits its phosphatase activity, therefore enhancing the PI3K 
signaling. Also the downstream targets of IGFR pathway, the FoxO transcription factors, are 
regulated by AcK via several mechanisms. It reduces their nuclear import, increases their 
ubiquitination and attenuates their binding to DNA (Yang and Seto, 2008). 
 
Mechanisms of influence of acetylation on protein function 
Here I would like to summarize various ways how AcK can influence protein function, 
which I will document with some representative examples (they are not ment as an 
exhaustive list). A few years old review (Spange et al., 2009) contains a thorough list of 
acetylated proteins known at that time and the biological implications of their acetylation 
(Table 2). Since then our knowledge of acetylated proteins exploded, which made 





Table 2: Various implications of protein acetylation (Spange et al., 2009). 
AcK can modulate enzymatic activity, which could be documented on p300 (Thompson et 
al., 2004) that is activated by autoacetylation just like kinases and phosphatases are 
regulated by phosphorylation. Such autoacetylation was discovered early on in in vitro 
assays, where the acetyltransferase acquired the radioactive acetyl just like the assayed 
protein. ATM kinase is activated by acetylation in response to DNA damage (Sun et al., 
2005). Acetylation of lysine that is important for ATP binding inhibits various cyclin-
dependent kinases (Choudhary et al., 2009). Acetylation serves as an on/off switch in many 
metabolic enzymes such as acetyl–coenzyme synthetase, which is switched on by Sir2 
mediated deacetylation (Starai et al., 2002) or all the metabolic enzymes described earlier 
(Zhao et al., 2010). This mechanism of regulation of acetyl–coenzyme synthetase is 
conserved from prokaryotes to mammals (Guan and Xiong, 2011). 
Acetylation can change subcellular localisation of proteins by covering the nuclear 
localisation signal (NLS). For example Inhibitor of Growth 4 (ING4) is acetylated at three 
lysines within its NLS (Kim et al., 2006). The splicing factor DEK relocates after acetylation 
from nucleoplasm to nuclear speckles (Cleary et al., 2005), which are nuclear storage 
compartment for RNA processing and transcription factors so acetylation likely inhibits DEK 
function in splicing. 
AcK crosstalks with other posttranslational modifications. Very well documented is the 
interplay of various modifications on N-terminal tails of histones known as the histone code 
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(Jenuwein and Allis, 2001). During gene silencing, acetylation is replaced by methylation on 
several lysines in histones, e.g. H3K9, H3K27, H4K20 (Kouzarides, 2007). HATs can be 
recruited to chromatin by chromodomains recognizing H3K4 and H3K36 methylation. H3K9 
and H3K27 acetylation is also enhanced by H3S10 and H3S28 phosphorylation, which 
represents a way how to relay a transient signalization through phosphorylation into lasting 
cellular response based on acetylation. Such acetylated and phosphorylated KS motive is 
present in more proteins (Yang and Seto, 2008). ADP-ribosylation can also crosstalk with the 
previously mentioned modifications. Their relationship can be antagonistic in the sense that 
they are competing for the same lysine residue, but also agonistic, because chromatin 
opening by acetylation promotes ADP-ribosylation (Hottiger, 2011).  
Several modifications interplay during p53 regulation, which is known in great detail. AcK 
in C-terminal domain by p300 is important for p53 stabilisation, because the same lysines 
are also targets of ubiquitination. But prior phosphorylation of N-terminal part is required 
for p300 binding to p53 (Yang and Seto, 2008). Other proof of connection of ubiquitination 
and acetylation is the widespread acetylation among nuclear ubiquitin ligases and 
deubiquitinating enzymes (Choudhary et al., 2009). Sumoylation of K524 of Ran GTPase1 is 
required for nuclear import, the same lysine residue can be also acetylated (Choudhary et 
al., 2009; Mahajan et al., 1997). Acetylation at four lysines decreases binding of 14-3-3 
proteins to their substrates (mostly serine or threonine-phosphorylated proteins), which was 
established by acetylation-mimicking mutations (lysine to glutamine mutation) in 14-3-3 
(Choudhary et al., 2009), which is an example of crosstalk of acetylation with 
phosphorylation and also documents other typical function of acetylation in altering protein-
protein interactions. 
Prime example are proteins containing a bromodomain, which is an acetylated lysine-
binding domain. It is typical for nuclear proteins involved in chromatin remodelling or 
transcription control, in cytoplasm or mitochondria such a domain has not been discovered. 
But there are many specific examples, e.g., acetylation within substrate binding domain of 
HSP90 abolishes its binding to the substrates (Choudhary et al., 2009; Scroggins et al., 2007). 
The interferon signalling is activated by acetylation, which promotes the interaction 
between the receptor and IFN regulatory factor 9 (IRF9) and also downstream between 
activated STAT proteins (Tang et al., 2007). Somewhat special example is acetylation of α-
tubulin, which is widespread from unicellular eukaryotes to vertebrates. It was observed 
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that stable microtubules are more acetylated than the dynamic ones and HDACs induce 
microtubule depolymerization. Acetylation also triggers the formation of a docking site for 
motor proteins (both kinesins and dyneins) on microtubules (Yang and Seto, 2008). 
Acetylation alters binding of proteins to DNA. Tip60-mediated acetylation in DNA-binding 
domain of p53 regulates, whether it will activate cell-cycle arrest or apoptotic cellular 
program (Sykes et al., 2006; Tang et al., 2006). The binding of nuclear hormone receptors to 
DNA is also regulated by acetylation, in most cases acetylation improves their binding 
capability (Wang et al., 2011). Similar observation was made for GATA transcription factors 
(Boyes et al., 1998) E2F transcription factors (Martinez-Balbas et al., 2000) or MyoD 
(Polesskaya et al., 2000). 
 
Acetylation alters RNA-protein interaction 
Last but not least acetylation alters RNA-protein interaction, which I will analyze in more 
detail. AcK neutralizes the positive charge on this residue and reduces the electrostatic 
interactions of negatively charged RNA with positively charged RNA-binding domain. The 
role of electrostatic interaction in RNA binding is well studied (Clery et al., 2011; Dominguez 
and Allain, 2006; Garcia-Garcia and Draper, 2003; GuhaThakurta and Draper, 2000; Law et 
al., 2006). It is important in the initial recognition phase of RNA and protein at longer 
distances up to 11 Å then short distance interactions gain more importance (the 'lure and 
lock' model (Law et al., 2006)). Electrostatic interactions do not have to be the exclusive 
mechanism. As stated earlier acetylation changes also size, hydophobicity and potential to 
form hydrogen bonds of the lysine side chain. Such alteration can trigger conformational 
change of the whole RNA-binding domain. 
The first example comes from HIV biology. The HIV protein Tat is essential for HIV 
transcription elongation. It binds a stem-loop structure at the 5′ end of HIV transcripts and 
recruits cyclin T1, part of P-TEFb complex (together with Cdk9) that phosphorylates C-
terminal domain of RNA polymerase II and triggers transcription elongation (Kiernan et al., 
1999). Tat is acetylated on two lysines with different outcomes. Acetylation on lysine 28 by 
PCAF enhances interaction with P-TEFb and lysine 50 acetylation weakens Tat interaction 
with HIV RNA, which enables Tat recycling. Recycling of Tat is important, because the 
expression of this protein is very low. HIV tanscription is also boosted by HDAC inhibitor TSA 
(Kiernan et al., 1999). Later it was shown that K28 is also important for RNA binding, because 
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it stabilizes the Tat-RNA-cyclin T1 ternary complex (D'Orso and Frankel, 2009). This is 
counteracted by K28 deacetylation by HDAC6 (Huo et al., 2011). 
The role of acetylation in RNA binding was also described in 2004 for Sam68 protein 
(Babic et al., 2004). It has diverse roles in cell signaling and regulation of cell cycle or pre-
mRNA splicing. It was shown that increased acetylation of Sam68 enhances its interaction 
with RNA. Acetylation of Sam68 was highest in tumorigenic breast cancer cell line 
implicating enhanced RNA binding of Sam68 in cancer cell proliferation. It was shown later 
that Sam68 is acetylated directly in its RNA-binding domain (Choudhary et al., 2009). 
Acetylation enhancing RNA binding is somewhat counterintuitive. Most likely acetylation 
enhances other interactions which compensate for the loss of electrostatic interaction of 
lysine side chain with phosphates in RNA. 
The opposite situation, where acetylation weakens RNA-protein interactions was 
documented for mouse VASA homolog (MVH or DDX4) in regulation of mRNA granule called 
chromatoid body (CB) in mouse spermatogenesis (Nagamori et al., 2011). Interestingly, the 
effect of acetylation on RNA binding was mRNA specific, some mRNAs remained bound even 
after MVH acetylation. MVH was localized to CB and bound approximately 800 mRNAs and 
triggered their translational arrest. A significant group among them were testis- or 
spermatogenesis-specific transcripts or translation regulators like eIF4B. Upon acetylation 
MVH released mRNA of eIF4B, which was involved in subsequent translational activation. 
Acetylation of MVH was developmentally regulated. The MVH acetyltransferase Hat1 
associated with CB only in certain developmental stage. Acetylation by Hat1 transmits here 
the endocrine or metabolic signals to the developing sperms (Nagamori et al., 2011). 
Reversible AcK is employed also in spreading of the dosage compensation complex 
around the X chromosome in Drosophila males (Buscaino et al., 2003). Dosage compensation 
in males upregulates expression from the single X chromosome to match the expression 
from two female X chromosomes. The MSL-3 protein is part of the dosage compensation 
complex, where it interacts with roX2 non-coding RNA. Upon acetylation of MSL-3 by MOF 
the interaction with roX2 is lost and MSL-3 dissociates and the complex falls apart. MSL-3 is 
then rapidly deacetylated, which allows the complex to reassociate at a nearby chromatin 
site (Buscaino et al., 2003). MSL-3 binds RNA with a chromodomain and the single acetylated 
lysine is not directly in the domain (lies nearby), which raises the question about the 
mechanism how acetylation interferes with RNA binding in this case. 
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Similar mechanism as in Drosophila is applied in de novo silencing of rDNA by NoRC 
chromatin remodeling complex (Zhou et al., 2009). The nonacetylated TIP5 subunit of NoRC 
is recruited to rDNA promoter by interaction with promoter RNA (pRNA; non-coding RNA 
transcribed from the rDNA promoter).  Then TIP5 is acetylated by MOF and TIP5 dissociates 
from pRNA which triggers the displacement of the promoter-bound nucleosome. Later SIRT1 
deacetylation allows TIP5 to reassociate with pRNA and histones around the promoter are 
modified with heterochromatin marks. The involvement of SIRT1 provides a link to metabolic 
state of the cell so that appropriate amount of rRNA is produced (Zhou et al., 2009). 
Other process where RNA-protein interactions are probably influenced by acetylation is 
pre-mRNA splicing. Inhibitors of both HATs and HDACs inihibit splicing in vitro (Kuhn et al., 
2009) and each inhibitor arrests the splicing reaction at specific stage. Though the protein 
composition of stalled spliceosomes has been establihed, the particular acetylated protein 
responsible for observed splicing defects remains to be identified (Kuhn et al., 2009). 
Acetylation influences RNA-protein interactions in diverse cellular processes. In my thesis 
I was testing whether it is significant also for the SR protein family of splicing regulators. 
 
SR proteins 
The serine/arginine-rich proteins are important regulators of both constitutive and 
alternative splicing (Long and Caceres, 2009; Shepard and Hertel, 2009). They regulate 
splicing of both major (U2-dependent) and minor introns (U12-dependent). Canonical SR 
proteins contain one or two RNA binding motives (RRM) on N-terminus followed by repeats 
of arginine-serine dipeptides called the RS domain. It must be at least 50 amino acids long 
with more than 40% of amino acids being serines and arginines (Manley and Krainer, 2010). 
This definition is rather arbitrary, because there is 51 proteins in humans containing both 
RRM and SR domain, but not in this order and not all of them function in splicing, which 
leaves us with 12 true SR proteins (Manley and Krainer, 2010). Other authors calculated 
slightly different numbers (Table 3). Older definitions of SR proteins, now abandoned, 
included their recognition by m104 monoclonal antibody or their ability to complement 
splicing-deficient HeLa cytoplasmic S100 extract. By that definition there were 7 classic SR 
proteins in humans, ASF/SF2, SC35, SRp20, SRp75, SRp40, SRp55 and 9G8 now renamed as 
SRSF1 to SRSF7 (Manley and Krainer, 2010). 
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 The well established role of SR proteins lies in 
assistance to general splicing machinery in 
recognition of correct splice sites in pre-mRNA. RS 
domain is crucial for recruitment of components of 
U1 and U2 snRNPs. It is heavily phosphorylated and 
serves as a surface for protein-protein interaction 
with other splicing factors also containing RS 
domains like U1-70K and U2AF35, proteins 
associated with U1 and U2 snRNPs. In recent years 
many other functions during the mRNA life cycle 
were attributed to SR proteins. They promote 
export of mRNA from the nucleus by interaction 
with TAP export receptor, they stimulate 
transcription elongation, NMD (nonsense-mediated 
decay) pathway, translation and have mRNA 
unrelated functions like maintaining genome 
stability, enhancing protein sumoylation and some 
of them are proto-oncogenes (Long and Caceres, 
2009; Twyffels et al., 2011; Zhong et al., 2009). SR 
proteins are essential and nonredundant at least in 
some tissues and developmental stages. Knockout 
mice for several SR proteins had all an early 
embryonic phenotype. SRSF1 is also essential for 
Caenorhabditis elegans development (Twyffels et 
al., 2011). 
SR proteins are predominantly nuclear with a tendency to accumulate in nuclear speckles, 
which is a storage compartment of splicing and transcription factors. SR proteins accumulate 
in speckles, while their RS domain is dephosphorylated and when it is rephosphorylated, 
they enter nucleoplasm and bind pre-mRNA. Most of SR proteins are also able to shuttle 
between nucleus and cytoplasm, and the RS domain serves as their nuclear localisation 
Table 3: The number of SR family members 
in various species (Richardson et al., 2011). 
The numbers marked with asterisk might be 
lower than the actual number of SR proteins 
in that particular species, because the 
sequences without methionine at the 
beginning were omitted. 
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signal (Twyffels et al., 2011). Reversible phosphorylation of the RS domain is key for SR 
protein versatility in their cellular functions. 
Just like the general splicing machinery, SR proteins are widespread among eukaryotes 
and their number varies among organisms. The eukaryotic taxa that completely lack SR 
proteins, lack them secondarily, because the common ancestor of eukaryotes presumably 
had SR proteins. The number of SR proteins is related to splicing complexity, alternative 
splicing and conservation of splice site and branch point sequences in each particular group 
(Table 3). The presence of SR proteins relieves the selective pressure on maintaining the 
sequence of splice sites close to consensus, which leads to splice site divergence and more 
alternative splicing (Busch and Hertel, 2012). It can be demonstrated on yeasts. The budding 
yeast Saccharomyces cerevisiae that has introns in about 2.5 % of genes and lacks alternative 
splicing, has no SR proteins (it possess some SR-like proteins), whereas the fission yeast 
Schizosaccharomyces pombe that has forty times more introns, has two SR proteins. Higher 
plants have the most SR proteins and even some plant-specific subfamilies. They acquired 
the extra members of the SR family presumably due to frequent genome duplications. It is a 
question though, if all their SR genes are essential, because it was described that one of the 
paralogs arising from the whole genome duplication is always expressed less and therefore 
probably redundant (Reddy and Shad Ali, 2011). The research on plant SR proteins is lagging 
behind the animal field so there is, among other things, no genome-wide information on 
their binding to RNA or acetylation, which was my prime interest, so we cannot draw here a 
comparison to animals. 
 
Binding of SR proteins to RNA 
The RNA recognition motive of SR proteins is responsible for their sequence-specific 
binding to RNA. They recognize only about four nucleotides long purine-rich sequences so 
the RNA sequence cannot be the sole determinant of SR protein binding. Very important is 
protein-protein interaction via RS domain and its phosphorylation state (Shepard and Hertel, 
2009). The SR binding site is usually degenerated, so the RRM must be able to bind various 
RNA sequences. This is achieved either by versatility of RRM that can accomodate various 
nucleotides or by the fact that different RNA sequences are bound in distinct conformations 
(Anko and Neugebauer, 2012). Mutation in the SR binding site is a common cause of disease 
(Cartegni et al., 2002) as demonstrated, e.g., for SRSF1 (Sanford et al., 2009). 
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Thanks to recent development of high-throughput methods, binding of SRSF1 (Sanford et 
al., 2009), SRSF3 and  SRSF4 to RNA (Anko et al., 2010; Anko et al., 2012) was studied on 
genome-wide scale in vivo by RIP-chip (RNA immunoprecipitation followed by hybridization 
to microarray) or CLIP-seq (photocrosslinking and IP followed by next-generation 
sequencing). CLIP is a unique method, that provides a snapshot of true situation in vivo. 
Regarding the consensus binding sequence, it confirmed older in vitro data so on this 
occasion the in vitro approach (SELEX) was valid and led to meaningful results. 
SRSF1 bound predominantly exonic sequences. Its binding sites were enriched in 
constitutive exons next to the alternative ones, which suggests a mechanism of alternative 
exon skipping modulated by SRSF1 due to activation of downstream splice site in 
constitutive exon. A significant group of mRNAs among the SRSF1 targets were RNA binding 
proteins participating in all steps of gene expression (Sanford et al., 2009). 
For SRSF3 and SRSF4 the CLIP study challenged the accepted model, that SR proteins 
predominantly bind to splicing regulatory sequences in exons (so called exonic splicing 
enhancers) and promote recognition of the adjacent splice site, because majority of SRSF3 
and SRSF4 were bound to intronic sequences and it is even more striking when you consider 
that in cells there is much more mRNA than pre-mRNA that SR proteins can bind to. So for 
SRSF3 and SRSF4 the splicing regulatory elements in introns are at least as important as 
those in exons. 
Each SR protein has several thousand targets in the cell and the targets of individual SR 
proteins overlap only slightly. This supports the view, that each SR protein regulates subset 
of splicing events in the cell and therefore the differences in expression level of splicing 
regulators in each tissue might be the key factor that causes tissue-specific alternative 
splicing. SRSF3 and SRSF4 bound also many non-coding RNAs. Most significant was probably 
MALAT1, RNA enriched in nuclear speckles, that was previously shown to bind SR proteins 
(Tripathi et al., 2010), then 7SK RNA, component of P-TEFb and snoRNAs (small nucleolar 
RNAs) particularly scaRNAs (small Cajal body-specific RNAs), that are processed from introns 
so SR proteins may play some role in snoRNA maturation. SRSF3 and SRSF4 bound also 
mRNAs from intronless genes like polyadenylated histone mRNAs in their 3′ UTR. So for 
histone mRNAs, SR proteins are important in further steps of their expression, probably for 
export from the nucleus and translation. SRSF3 was  revealed as a regulator of other SR 
proteins. It was known previously, that each SR protein regulates its quantity in the cell by 
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promoting the inclusion of alternative exon containing premature termination codon into its 
mRNA. Such exon then triggers nosense-mediated decay of that RNA (Lareau et al., 2007; Ni 
et al., 2007). SRSF3, apart from itself, regulated SRSF2, 5 and 7. It bound also other RNA 
binding proteins, splicing factors and proteins from the spliceosome, which makes it an 
important modulator of RNA metabolism (Anko et al., 2012). 
So far the structure of a complete SR protein bound to RNA has not been resolved, 
because RS domain is intrinsically disordered, heterogeneously phosphorylated and 
insoluble and therefore cannot be visualized by crystallography or NMR. Yet there are 
structures of RRM domain of SR proteins SRSF1, 2, 3 and 7 in complex with short RNA 
oligonucleotides (Clery et al., 2011; Hargous et al., 2006; Phelan et al., 2012; Tintaru et al., 
2007) that reveal which residues of RRM are involved in RNA binding and also uncover 
structural basis of recognition of RNA sequence by RRM. In general RNA is bound by an 
interaction surface formed by several β-sheets that are supported from the opposite side by 
two α-helices. Two α-helices and several β-sheets oriented as described are a canonical fold 
of an RRM, but this fold can be contacted by RNA in different ways. 
 The proteins used for structural studies did not carry acetylations or other eukaryotic 
posttranslational modifications, 
because they were purified from 
bacteria. The lysines that were 
reported to be acetylated in vivo 
were not directly contacting RNA, but 
amino acids in close proximity were 
essential for RNA binding. 
Interestingly the amino acids directly 
binding RNA are not more conserved 
than the surrounding residues and in 
general there are more modes of 
RNA binding among RRM domains. 
They differ in involvement of certain 
loops between β-sheets of RRM and 
contribution of amino acids on the N- 
and C- termini of the RRM to RNA binding. The structure of SRSF1 RRM2 is the closest 
Fig. 1: The structure of SRSF1 RRM2 with the acetylated lysine 
residue highlighted in red (Tintaru et al., 2007). PDB entry 2O3D, 
visualization done in PyMOL. 
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approximation of so far unknown structure of SRSF5 RRM2, which is the subject of my study. 
In SRSF1 the acetylated lysine is located in  β-sheet β3′ (Tintaru et al., 2007), where it can 
potentially regulate RNA binding (Fig. 1). 
. 
Acetylation of SR proteins and its function 
Majority of the 7 classic SR proteins in humans are acetylated in the RRM domain with 
the exception of SRSF4 that is not acetylated and SRSF6 that is acetylated outside the RRM 
domain. SRSF7 is acetylated in RS domain as well (Fig. 2). Moreover, acetylation sites are 
conserved in related SR proteins. The identical lysine residue is acetylated in SRSF3 (K23) and 
SRSF7 (K24), similarly SRSF1 (K38) and SRSF2 (K36), and SRSF5 (K167) and SRSF1 (K179). In 
the newly included 
SRSF8 – SRSF12 no 
acetylation has 
been detected so 
far, but it might due 
to the fact that they 
are generally less 
studied.   
SRSF2 is the only 




(Edmond et al., 2011b). Acetylation by Tip60 had a destabilizing effect on SRSF2 and 
promoted its proteasomal degradation in human lung carcinoma cell line. Mutation of the 
acetylated lysine to arginine stabilized the protein. In agreement with the previous 
observation, HDAC6 mediated deacetylation stabilized SRSF2 as well. Often, acetylation has 
stabilizing effect on proteins by inhibiting ubiquitination of the same lysine residue, but it is 
well established that acetylation can have destabilizing effect on proteins too. It is not 
known, whether SRSF2 is degraded by ubiquitin-dependent or independent pathway. Tip60 
has also an indirect effect on SRSF2 phosphorylation. Overexpression of Tip60 caused 
relocation of SR protein kinases to the cytoplasm and subsequent SRSF2 
Fig. 2: The family of human SR proteins with the acetylation sites marked. Edited 
from (Twyffels et al., 2011). 
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hypophosphorylation. Phosphorylation is required for SR protein function so Tip60 is a 
negative regulator of SRSF2 on more levels. It causes destabilization as well as 
dephosphorylation of SRSF2 (Edmond et al., 2011b). Finally they showed that after treating 
cells with cisplatin, SRSF2 accumulates in nonacetylated and phosphorylated form. However, 
the role of SRSF2 acetylation in interaction with RNA was not analyzed and currently there 
are no data avialble that would probe role of SR protein acetylation in their RNA binding. 
Disturbingly, Edmond and colleagues reported acetylation of different lysine residue than 
was previously described (Choudhary et al., 2009). 
A follow-up study from the same lab assessing the influence of HDAC inhibitor sodium 
butyrate (NaBu) and SRSF2 on senescence (Edmond et al., 2011a) came to different 
conclusions. In human lung carcinoma cell line treated with NaBu, SRSF2 accumulated in 
acetylated and hypophosphorylated form. It is unclear why the acetylated SRSF2 is stabilized 
in this case. Other HDAC inihibitors trichostatin A (TSA) and nicotinamide (NAM) had no 
effect on SRSF2 acetylation even though at least TSA should inihibit HDAC6 previously shown 
to deacetylate SRSF2. This confusing result can be explained by the finding, that in this case 
NaBu did not function as an HDAC inhibitor, but it rather upregulated the Tip60 
acetyltransferase. TSA and NAM did not change Tip60 expression (Edmond et al., 2011a). 
Interestingly, our recent data showed that NaBu did not change acetylation of another SR 
protein SRSF5 (Hnilicova et al., 2011). 
In this work I developed and tested a hypothesis, that lysine 167 of SRSF5 and its 
acetylation is an important regulatory modification, that can influence binding of SRSF5 to 
RNA, splicing of SRSF5 targets and  also the SRSF5 subcellular localisation or phosphorylation 
of its RS domain. To test it, I mutated the putative acetylation site of SRSF5 to arginine and 
glutamine. The arginine mutation mimics nonacetylated lysine, whereas the glutamine 
mutation should imitate acetylated lysine. To distinguish mutants from endogenous proteins 
I tagged the exogenous proteins with EGFP. I tested various properties of those mutants in 
comparison to the wild type protein. Their binding to RNA in vitro by fluorescence anisotropy 
and in HeLa cell lines by RIP. Their localisation in the cell by immunofluorescence microscopy 
and their dynamics by fluorescence recovery after photobleaching (FRAP), the acetylation 
and phosphorylation state of the RS domain by western blot and a direct effect of mutants 
on splicing by splicing reporter containing SRSF5 binding site. 
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Materials and methods 
Cell culture and drugs 
HeLa cells were cultured in DMEM high glucose medium (Sigma) supplemented with 10% 
fetal calf serum and penicillin/streptomycin. Cells were grown in an incubator at 37 °C in 5% 
CO2 atmosphere. The SRSF5-EGFP BAC HeLa cell line was kindly provided by Karla 
Neugebauer, MPI-CBG, Dresden. 
 The inhibitor of transcription elongation, 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole 
(DRB) (Sigma) was used at 50 µM final concentration in the medium. Cells were incubated 
with DRB for 4 hours. The inhibitor of HDACs, sodium butyrate (NaBu) (Sigma) was used at 
5mM final concentration in the medium and cells were treated for 6 hours. 
 
Protein tagging and mutagenesis 
The SRSF5 gene was amplified from mouse cDNA using primers F 5′–CCC AAG CTT ATG 
AGT GGC TGT CGA GTG–3′ and R 5′–CCG GAA TTC CAT TGC CAC TGT CAA CTG A–3′ and 
cloned into EGFP-N1 vector (Clontech) using EcoRI and HindIII restriction sites. The accuracy 
of the construct was checked by restriction digest and by sequencing. 
The point mutation was created by PCR mutagenesis. It was performed in 50 µl PCR 
reactions using Phusion polymerase (Thermo Scientific), 20 ng plasmid DNA template and 
100 nM primers. Two sets of primers were used with the one nucleotide mismatch in the 
middle. For the mutation of Lys to Arg F 5′–GCT ATT GAG AAA CTT TCT GGA AGG GAA ATT 
AAC GGG–3′ R 5′–AGA AAA ATC GAT TTT TCT CCC GTT AAT TTC CTT TCC AGA AAG TTT CTC 
AAT AGC–3′ and for the mutation of Lys to Gln F 5′–TGC TAT TGA GAA ACT TTC TGG ACA GGA 
AAT TAA CGG GAG AAA AAT–3′  R 5′–ATT TTT CTC CCG TTA ATT TCC TTT CCA GAA AGT TTC 
TCA ATA GCA–3′. PCR reaction was performed according to the Phusion polymerase 
manufacturer`s recommendations with primer annnealing temperature 65 °C for 18 cycles. 
After cleanup of the reaction by QIAquick PCR purification kit (Qiagen) the template DNA 
was cleaved by methylation-sensitive restriction enzyme DpnI (NEB) overnight at 37 °C. The 
resulting mixture was used for heat shock transformation of DH5α cells. Accuracy of the 
construct was checked by sequencing and the SRSF5 gene sequences were recloned into 





Transfection of siRNA, plasmid DNA and creating stable cell lines 
Transfection of siRNA and DNA was done as previously described (Hnilicova et al., 2011). 
The siRNA against SRSF5 (Silencer® Select Ambion) sequence: sense 5′–GAA UUA GUU UA 
AUG CCU UAtt–3′ and antisense 5′–UAA GGC AUU AAA CUA AUU Ctg–3′. As a negative 
control I used Negative Control#1 siRNA (Ambion). 
For production of stable cell lines expressing WT or mutant SRSF5-EGFP, cells were plated 
on a 10 cm Petri dish and after 24 hours transfected with 5 µg of appropriate plasmid. After 
another 24 hours G418 antibiotic was added to the culture medium at 1 mg/ml to kill the 
cells not expressing the construct. Culture medium with fresh antibiotic was exchanged 
every 48 hours and after two weeks only colonies of stably transformed cells remained on 
the dish. Cells were then sorted on FACS and only the ones exhibiting higher fluorescence 
were used in further experiments. 
 
Antibodies and western blotting 
The Acetylated-Lysine Antibody (Cell Signaling technology, rabbit polyclonal) was diluted 
1:250 in 5% milk dissolved in PBS supplemented with 0.05% Tween and incubated with the 
membranes O/N at room temperature. The supernatant of m104 hybridoma (mouse 
monoclonal antibody recognizing a phosphorylated epitope on SR proteins, kindly provided 
by K. Neugebauer, MPI-CBG Dresden) was diluted 1:10 in 5% BSA dissolved in TBS 
supplemented with 0.1% Tween and 25mM NaF and incubated with the membranes for 30 
minutes at room temperature. The GFP antibody B-2 (Santa Cruz Biotechnology, mouse 
monoclonal) was diluted 1:1000 in 5% milk dissolved in PBS supplemented with 0.05% 
Tween and incubated with the membranes for 1 hour at room temperature. Anti-GAPDH 
G9545 antibody (Sigma, rabbit polyclonal) was diluted 1:1000 in 5% milk dissolved in PBS 
supplemented with 0,05% Tween and incubated with the membranes 1 hour at room 
temperature. Appropriate secondary antibodies conjugated with HRP (Jackson 
ImmunoResearch) were used at 1:5000 dilution and incubated with the membranes for 1 
hour at room temperature. The western blots were developed with the ECL substrates 







Cells were grown on cover slips to 30–50% confluency. Between each of the following 
steps they were washed 3 times with PBS. Cells were fixed in 4% paraformaldehyde/PIPES 
for 10 minutes, then permeabilized with 0.5% TritonX-100 (Sigma) in PBS for 5 minutes and 
blocked with 5% normal goat serum (Jackson ImmunoResearch) for 15 minutes. Next the 
supernatant of mouse hybridoma recognizing SC-35 (kindly provided by K. Neugebauer, MPI-
CBG Dresden) was diluted 1:10 in 5% normal goat serum and the cover slips were incubated 
on a drop of antibody for 1 hour in a wet chamber. Then they were incubated with a 
secondary antibody diluted 1:200 conjugated with DyLight549 (Jackson ImmunoResearch) 
for 1 hour in a wet chamber. Finally they were washed in dH2O, dried and mounted into 
Fluoromount (SouthernBiotech) with DAPI. Images were acquired as described previously 
(Huranova et al., 2009) and the deconvolution was performed in Huygens software package 
(Scientific Volume Imaging). 
 
Splicing reporter assay, RNA isolation and RT-PCR 
RNA was isolated from 80–100% confluent cells grown on one well of 12-well plate for 3 
days. One day after plating, cells were transfected with siRNA against SRSF5 or with negative 
control#1 siRNA (Ambion). After one more day cells were transfected with 500 ng of splicing 
reporter. Cells were harvested 24 hours after transfection of splicing reporter and RNA was 
isolated by TRIzol reagent (Ambion) according to manufacturer`s protocol. 1 µg of RNA was 
used in RT reaction with SuperScript III (Invitrogen) according to manufacturer`s protocol. 
cDNA from the splicing reporter was amplified by Taq polymerase (Fermentas) with primers 
F 5′–TGG AGT ACA ATG TCA GTG TTT–3′ and R 5′–CTG GAC CAA TGT TGG TGA ATC–3´. The 
amount of SRSF5 mRNA was assessed by qPCR where different forward primers 
distinguished between endogenous and exogenous mRNA and the reverse primer was the 
same for both variants. The specificity of primers was confirmed with mouse and human 
cDNA. Endogenous human F 5′–GGA TGC AGA TGA TGC TGT GT–3′ mouse F 5′–GGA TGC AGA 






Protein expression and purification 
Two RRM domains (first 180 amino acids) of SRSF5 were cloned into pET-42b vector using 
NcoI and NotI restriction enzymes to create a fusion protein tagged with GST on N-terminus. 
Following primers were used F 5′–CAT GCC ATG GAT GAA AAC CTG TACT TCCA GGG CAT GAG 
TGG CTG TCG AGT G–3′ R 5′–ATA GTT TAG CGG CCG CTT ATT TGC TGC CTT CAA TTA A–3′. 
BL21 bacterial cells (Invitrogen) were transformed with the plasmid and grown in LB medium 
with 25 µg/ml kanamycin. Protein expression was induced at OD 0.5–1 with 250 µM IPTG. 
After shaking for 3 hours at 37 °C cells were spun, rinsed with dH2O and stored in -80 °C. 
Pelets were resuspended in GST loading buffer (PBS supplemented with 5 mM dithiothreitol 
(Sigma), 0.1% Triton X-100 (v/v) (Sigma) and protease inhibitor cocktail (Calbiochem)). Cells 
were sonicated and the lysate was cleared by centrifugation at 20,000 g for 30 minutes at 4 
°C. Lysate was incubated rotating with glutathione agarose beads (Sigma) for 3 hours at 
room temperature. Beads were transferred onto a column and washed 8 times with 15 ml of 
GST loading buffer and 2 times with 15 ml of Elution buffer (Tris pH 8.0, 50 mM NaCl). GST 
fusion protein was eluted with Elution buffer supplemented with 10 mM glutathione 
(Sigma). 
 Protein concentration was determined by standard Bradford assay using 600 µl Bradford 
reagent (Sigma). BSA standards from 200 to 1000 µg/ml were used for measurement of the 
calibration curve. Protein purity was assessed by SDS-PAGE on 10% gels and PageBlue 
Protein Staining Solution (Fermentas) was used for gel staining. To exchange buffers and 
concentrate the proteins, samples were repeatedly spun at 15,000 g in 500 µl Vivaspin 
columns (Sartorius) with a polyethersulfone membrane and 10 kDa molecular weight cutoff. 
 
Thermofluor measurement 
The thermofluor measurement is a fluorescence-based thermal stability assay (Pantoliano 
et al., 2001). Thermal stability of a protein is measured by incubating the protein with 
hydrophobic fluorescent probe that is quenched in aqueous solution while steadily 
increasing the temperature. As the protein unfolds, the hydrophobic residues from its core 
interact with the fluorophore, which is no longer quenched and fluorescence of the sample 
increases. The protein transforms from folded to unfolded state rapidly around a particular 
temperature and the midpoint of this transition is defined as the melting temperature, Tm 
(Ericsson et al., 2006). 
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The protein Tm was assessed in pannel of buffers (Ericsson et al., 2006) in 96 well plate 
format. The purified, concentrated protein was diluted into tested buffers to a 50 µg/ml final 
concentration and SYPRO Orange Protein Gel Stain (Invitrogen) was added at final 
concentration 8×. The total volume of each sample was 25 µl. 24 buffering agents of varying 
pH with addition of either 200 mM or 400 mM NaCl were tested. Fluorescence was 
measured in Light Cycler 480 (Roche) with temperature increasing from 20 to 95 °C at a 
ramp rate of 0.01 °C/s. 
 
Fluorescence anisotropy 
The equilibrium binding of SRSF5 protein to RNA was analyzed by fluorescence 
anisotropy. Measurements were conducted on a FluoroMax-4 spectrofluorometer (Horiba 
Jobin-Yvon) instrument equipped with a thermostatted cell holder with a Neslab RTE7 water 
bath (Thermo Scientific). The system was operated using FluorEssence V3.5 software (Horiba 
Jobin-Yvon). The 5’-fluorescein labeled RNA probe 5′–UGA CUC CAC UGC–3′ (Sigma) was 
designed as two consecutive SRSF5 consensus binding sites based on literature (Caputi et al., 
2004; Goren et al., 2006; Liu et al., 1998; Tacke et al., 1997). The RNA probe was excited at 
488 nm and its emission was recorded at 520 nm. The widths of monochromatic slits were 9 
nm for both excitation and emission and integration time was set to 3 s. The measurements 
were done at 10C in 100 mM bicine buffer (pH 7.6) containing 300 mM NaCl, 0.5 mM DTT 
and 10% glycerol. 10 nM labeled RNA (1.4 ml) was titrated with increasing amounts of 
purified protein and the reaction was carried out in a stirred 1.5 ml quartz cuvette. Each data 
point is an average of three measurements. The experimental data were analyzed in 
SigmaPlot 11 software (Systat Software) and isotherms were fit to a single-site binding 
model according to Heyduk and Lee using nonlinear least squares regression. The data were 
normalized for visualization purposes. 
 
FRAP 
For FRAP measurements, cells were plated on glass bottom dishes (InVitro Scientific) and 
measured 24 hours later at 30–50% confluency. Prior to FRAP measurements, the medium 
was exchanged for colorless DMEM high glucose medium (GIBCO). Cells were imaged on 
Leica TCS SP5 confocal microscope, which is equipped with a chamber for live cell imaging. 
Objective HCX Plan-Apochromat 63× NA 1.40-0.6 oil, Lbd Blue CS was used. Images were 
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acquired with open pinhole (250 µm) in 12-bit resolution in 512 × 512 format at a 1000 Hz 
scan speed (imaged every 0.277 s). The 488 nm laser line of argon laser (100 mW) at 6% 
laser power was used for imaging and 458 nm, 476 nm, 488 nm, and 514 nm lines were used 
for bleaching at 100% laser power. In each measurement, 12 prebleach images were taken, 
followed by 3 bleach pulses and 400 postbleach images. In all the experiments half of the 
nucleus was bleached. This method was described previously (Phair et al., 2004a; Phair et al., 
2004b) and is suitable for fast moving, transiently interacting nuclear proteins. Around 10 
cells were measured in each experiment and the measured fluorescence was normalized to 
the whole nucleus fluorescence and background was subtracted. The FRAP curves were 
fitted with double exponential function using SigmaPlot and the half-times of fluorescence 
recovery were extracted. 
 
Immunoprecipitation and RNA immunoprecipitation (RIP) 
Immunoprecipitation was performed as described previously (Huranova et al., 2009). 
RNA immunoprecipitation was performed from 90–100% confluent PD15 of cells grown for 
48 hours. The cell lines expressing SRSF5-GFP were used and normal HeLa cells not 
expressing GFP served as a negative control. All the steps were performed on ice or at 4 °C. 
Cells were washed three times with cold  PBS, scraped into 1 ml of cold PBS and centrifuged 
at 1000 g for 2 minutes. Cell pellets were resuspended into RIP lysis buffer (20 mM Tris-HCl 
pH 7.5, 200 mM KCl, 2 mM MgCl2, 1% (v/v) NP-40) to the mass of 1.5 g and 7.5 µl protease 
inhibitor cocktail (Calbiochem) and 3 µl RNasin (Promega) were added. The solution was 
sonicated in 0.5 s pulses and centrifuged at 20,000 g for 10 minutes. The supernatants were 
transferred into new tubes and 30 µl of Sepharose G beads (GE Healthcare) prewashed in 
RIP lysis buffer were added for precleaning and the solutions were incubated rotating at 4 °C 
for 1 hour. During the precleaning their protein concentration was measured and all the 
samples were diluted afterwards to identical protein concentration with RIP lysis buffer. Ten 
percent of the samples were put in the freezer as input. 
7.5 µg of anti-GFP antibody (obtained from David Drechsel, MPI-CBG, Dresden, Germany) 
was added to all samples and they were incubated rotating at 4 °C for 2 hours. Samples were 
centrifuged at 10,000 g for 5 minutes to get rid of the potential protein precipitate and 
supernatants were mixed with 40 µl of Sepharose G beads preblocked with 1000 µg/ml BSA 
(NEB) and 100 µg/ml yeast RNA (Ambion) and incubated rotating at 4 °C for 1 hour. The 
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beads were washed 6 times with RIP lysis buffer and one quarter of them was saved for 
protein analysis by western blot and the rest was mixed with 300 µl of NET-2 buffer (50 mM 
TRIS–Cl pH 7.5, 150 mM NaCl, 0.05% Nonidet P-40) supplemented with 1% SDS and 300 µl of 
acid phenol:chloroform (Sigma) and incubated shaking at 37 °C for 1 hour. From this step of 
RNA isolation the input samples were processed as well. The mixture was centrifuged at 
10,000 g for 10 minutes at room temperature and the aqueous phase was transferred into a 
new tube and RNA was precipitated with 1 ml of 96% ethanol, 30 µl of 3 M sodium acetate 
and 20 µg of glycogen (Ambion) overnight in -80 °C. 
The precipitated RNA was resuspended in 7.5 µl of nuclease-free water and the trace DNA 
was eliminated by DNAfree kit (Ambion) according to manufacturer`s instructions. 4 µl of 
RNA was used in reverse transcription with gene-specific reverse primers later used in qPCR 
and 4 µl of RNA was stored as a -RT control for qPCR. The RT reactions were diluted 5 times 
with PCR H2O and served as a template in qPCR reactions. Light Cycler® 480 SYBR Green I 
Master mix (Roche) was used according to manufacturer`s instructions. The qPCR was run in 
Light Cycler® 480 (Roche) with annealing temperature 61 °C for 45 cycles. All primers were 
tested for efficiency and only those with efficiency between 90 and 110% were used. The 
specificity of primers was always checked by melting curve analysis. The following primer 
pairs were used at 1 µM concentration. SRSF5 F 5′–AGA GTC AGC TGG CAG CCT GTC TGT G–
3′ SRSF5 R 5′–ATC ACT GTA GGA GCT GAC TGG CAA A–3′ from (Lareau et al., 2007) and for 
checking that the RNA concentration in inputs is the same, I used common GAPDH primers F 
5′–GAA GGT GAA GGT CGG AGT–3′ R 5′–GAA GAT GGT GAT GGG ATT TC–3′. The RIPs were 
quantified as percent of input normalized to GFP signal from the RIP protein fraction. This 
was necessary, because each cell line had slightly different level of expression of SRSF5-EGFP 





First step in studying the acetylation of SRSF5 was confirming the mass spectrometry data 
about the acetylation (Choudhary et al., 2009) on western blot. I had available a HeLa cell 
line with genome-integrated bacterial artificial chromosome containing full-length mouse 
SRSF5 gene tagged with EGFP with its own promoter and other 
regulatory sequences (Poser et al., 2008). I called it WTBAC. The 
cells express the protein at physiological level. It was shown that 
such proteins behave in all aspects as the endogenous ones 
(Anko et al., 2010). I performed immunoprecipitation from the 
cells via the EGFP tag and I confirmed the acetylation on 
western blot (Fig. 3). I also tested if SRSF5 acetylation is 
responsive to sodium butyrate (NaBu), a broad spectrum 
inhibitor of HDACs, and found out that SRSF5 acetylation does 
not change after NaBu treatment  (Fig. 3). 
To study the protein further, I cloned the SRSF5 cDNA from 
mouse 3T3 cells into EGFP vector to tag the protein with EGFP 
on C-terminus and mainly for subsequent mutagenesis. Mouse 
SRSF5 has 270 amino acids (31 kDa) and is on protein level 
almost identical to the human protein apart from 6 
conservative substitutions or indels in the variable RS domain. I 
chose the strategy of introducing the mouse protein into human 
cells for future simplier knockdown of endogenous protein and 
because I wanted to use the WTBAC as a positive control in 
certain experiments, which is mentioned later. 
SRSF5 has single acetylation site at lysine 167 in the RRM2 domain. To study how changes 
of amino acid side chain in this position alter protein function, I created two different point 
mutations of K167 by PCR site-directed mutagenesis (Fig. 4a). The mutation to arginine 
preserves positive charge at that position, but blocks acetylation. The mutation to glutamine, 
on the other hand, mimics acetylation. I named them R and Q respectively and compared 
various properties of the mutants with wild type SRSF5. 
 To control for the influence of EGFP tag on SRSF5 function, I included a positive control 
The WTBAC protein, which is several kDa heavier because it contains a longer linker between 
Fig. 3:  Acetylation of SRSF5-
GFP in cells treated with 
sodium butyrate (NaBu) and in 
nontreated cells. AcK, anti-
acetylated lysine antibody. 
Acetylation was quantified by 
denzitometric analysis in 
ImageJ. The western blots with 
AcK antibody were normalized 
to the total amount of 
immunoprecipitated protein 
inferred from GFP signal; 
average of four biological 
experiments; error bars 
represent standard deviation. 
The acetylation in nontreated 
cells was set as 1. Adapted from 
(Hnilicova et al., 2011). 
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I created HeLa cell lines stably expressing WT, R and Q variants of SRSF5 at similar levels 
close to physiological and I observed localization of the proteins in cells (Fig. 4a). All the 
Fig. 4: (a) Subcellular localisation of WT and mutant variants of SRSF5-GFP and their colocalization with a 
speckle marker SRSF2 and DNA counterstained with DAPI (blue), scale bar 10 µm. On the right, the point 
mutations confirmed by DNA sequencing. (b) The expression level of SRSF5-GFP in the lysates from the cell 




proteins had, as expected, nuclear localization and they accumulated in certain nuclear 
regions that were confirmed to be nuclear speckles by staining against a nuclear speckle 
marker SRSF2. The positive control WTBAC was identically distributed. The natural 
localization of WT, R and Q indicated that they were functional in splicing and other 
processes they participate in. The localization of SRSF5 was transcription-dependent. After 
inhibition of transcription by DRB, SRSF5 accumulated in enlarged speckles (not shown), 
which is a general property of splicing factors.  
The lack of difference in subcellular localization among WT, R and Q was surprising (Fig. 
4a). It indicated that even the proteins with the mutation are functional and if there is some 
difference among them, it does not manifest 
itself on protein localization. 
 
Acetylation and phosphorylation of SRSF5 
Next, I examined the posttranslational 
modifications of the four studied SRSF5-EGFP 
proteins. I immunoprecipitated them with anti-
GFP antibody and probed the modifications on 
western blot with anti-acetylated lysine 
antibody (AcK) to confirm that the mutants are 
not acetylated and anti-phosphorylated SR 
antibody (m104) to see the level of 
phosphorylation in their RS domain (Fig. 5a). I 
was able to reliably detect the acetylation of 
WTBAC protein unlike the WT protein. In case 
of WT and also R protein, there was a very faint 
signal that is hard to interpret. It could come 
from acetylation site other than K167, however, 
if that is the case, similar signal should be 
detected in the Q mutant as well, but there was 
none. Alternatively, it is unspecific binding of 
the AcK antibody. The reason why WT protein 
Fig. 5: (a) Acetylation and phosphorylation of 
immunoprecipitated SRSF5-EGFP; HeLa denotes a 
negative control immunoprecipitation from 
standard HeLa cells without GFP expression; AcK, 
anti-acetylated lysine antibody; m104, anti-
phosphorylated SR protein antibody (b) 
Denzitometric analysis in ImageJ of western blots 
with m104 antibody normalized to the total 
amount of immunoprecipitated protein inferred 
from GFP signal; average of two biological 
experiments; error bars represent standard 




was not acetylated like the WTBAC remains an open question because the proteins differ 
only in the linker sequence between SRSF5 and EGFP. 
The WT, R and Q proteins were similarly phosphorylated; there was not a statistically 
significant difference among them. The WTBAC was phosphorylated two to three times 
more (Fig. 5b). The presence of phosphorylation again proved that the proteins are 
functional. The higher phosphorylation of WTBAC did not manifest in its different 
localization, even though it is well established that SR protein phosphorylation is one of 
determinants of their subcellular localization. Probably the difference was not big enough to 
be perceptible. Also we must not forget that the tagged protein is competing with the 
endogenous protein for binding sites, which can influence its localization as well.  
 
Dynamics of SRSF5 proteins in vivo 
I measured SRSF5 dynamics in the cell by FRAP. In the experiment, half of the nucleus was 
bleached (Fig. 6c), because I wanted to cover the proteins in nucleoplasm and speckles at 
the same time and also because the fluorescence recovery was too fast to measure correct 
recovery curve when I bleached a small circular area. The FRAP curves I gained were very 
similar for all four SRSF5 proteins (Fig. 6a). The fluorescence recovery was very fast and 
there was no or very small immobile fraction. Because each cell line bleached with slightly 
different efficiency, I used the half time of fluorescence recovery to compare the FRAP 
curves with each other. Half times were not significantly different among the proteins.  
This method allows to study the interaction of SRSF5 proteins with RNA in vivo, because 
the dynamics of SR proteins in cells are influenced by two factors, their diffusion and binding 
to RNA or proteins. The diffusion should be the same for the four SRSF5 proteins I studied. 
Molecular weight of WT, R and Q is almost the same, because they differ only in one amino 
acid substitution and the WTBAC is only a few kDa heavier, which is negligible, if you take 
into account that you measure mixed population of proteins that are differentially 
phosphorylated and acetylated. The mutation in RRM2 in R and  Q proteins could alter their 
interaction with RNA but should not change interaction with proteins, via the RS domain. So 
the observed difference in fluorescence recovery should be caused by altered interaction 
with RNA. The conclusion is that I was not able to detect differential interaction of SRSF5 




To confirm that SRSF5-GFP proteins bind to RNA in vivo, I treated cells with DRB, an  
inhibitor of transcription elongation, for 4 hours thus depleting the nucleus of both pre-
mRNA and mRNA and observed the protein dynamics again. In such condition pure diffusion 
of the proteins is observed. In all four cases the proteins moved faster and the half time of 
recovery shortened (Fig. 6b).  In case of WTBAC and Q proteins the difference was 
statistically significant (p=0,007 and 0,002 respectively), unlike the WT and R, but the trend 
was the same in all four cases. The difference in half times with and without DRB was quite 
small, but the SRSF5 proteins were very fast even before the treatment, which means they 
interact shortly with other nuclear factors. FRAP results showed that SRSF5-GFP proteins 
Fig. 6: (a) Average FRAP curves of SRSF5-GFP proteins and calculated half times of fluorescence recovery, both 
average of 8 to 12 cells, error bars represent standard deviation (b) The same measurements as previously but 
after inhibition of transcription by DRB (c) In the FRAP experiments half of the nucleus was bleached (green) 
the fluorescence was normalized to whole cell fluorescence (blue) and background was subtracted (orange). 
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indeed bind to RNA and form transient interactions with it, but did not detect difference in 
RNA binding among them.  
 
Quantification of SRSF5 interaction with RNA by RNA immunoprecipitation (RIP) 
I decided to measure 
SRSF5 interaction with RNA in 
cell lysates by RIP. I followed 
a native protocol without 
crosslinking. It captures the 
situation in vivo quite 
faithfully, although the 
interactions can still change 
during the lysate incubation 
with antibody. I used the 
EGFP tag for 
immunoprecipitation and 
after the 
immunoprecipitation step, I 
isolated RNA from the 
immunoprecipitates and 
performed qRT-PCR (Fig. 7b). 
I quantified the RNA as 
percent of input. I also 
performed western blot with 
the protein fraction to quantify how much protein I pulled down, which was important for 
normalization of the results (Fig. 7a). From the WT and R cell lines I immunoprecipitated 
almost identical amount of SRSF5-EGFP, but from Q cells it was about 1.5 times more of the 
construct. This difference was not due to expression in the cell lines. It was rather the R cell 
line that had the highest expression of SRSF5-EGFP (Fig. 4 and 9), but for unknown reason 
the immunprecipitation was most efficient in the Q cell line. First, I optimized the protocol 
for better signal-to-noise ratio and then I performed three biological replicates. Few RNA 
targets of SRSF5 were known at the time and most of them were not sufficiently expressed 
Fig. 7: (a) The amount of SRSF5 mRNA pulled down by SRSF5-GFP 
quantified as percent of input and normalized to amount of protein 
immunoprecipitated inferred from western blot. The WT value was set 
to 1. NC represents negative control,the HeLa cells not expressing GFP. 
Average of three biological experiments is shown, error bars represent 
standard deviation. Only a representative  western blot from one 
experiment is shown (b) Scheme of the RIP experiment. 
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in HeLa cells to allow precise quantification by qPCR. So I measured SRSF5 binding to one 
target. It was an alternative exon in its own mRNA whose inclusion triggers nonsense-
mediated decay (Lareau et al., 2007).  
The mutant proteins R and Q pulled down approximately one third of SRSF5 mRNA as the 
WT. That was a first difference between WT and mutants observed. Neither the localization 
nor the dynamics of the proteins were able to detect such difference in RNA binding. 
 
Fig. 8: (a) Scheme of the GST construct, His 6× is His-tag, Thrombin and TEV indicate protease cleavage sites 
and RRM1 and RRM2 denote the RNA binding domains of SRSF (first 180 amino acids). scheme is not to scale 
(b) On the left, SDS-PAGE of bacterial lysates before and after induction of GST-SRSF5 expression by IPTG, 
soluble and insoluble denote the supernatant and pelet after cell lysis by sonication, all three proteins behaved 
in the same way. on the right, purified GST-SRSF5 proteins. (c) An example of curves acquired by thermofluor 
measurement, bicine pH 8.0 was the best performing buffering agent. 
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GST-SRSF5 protein purification and buffer optimization 
I decided to study binding of SRSF5 to RNA in vitro as well. For in vitro experiments I 
created another set of constructs containing the two RRM domains (amino acids 1–180) of 
WT, R and Q tagged on N-terminus with glutathione S-transferase (GST). The following 
construct had a size of 54.6 kDa and pI 8.3 (Fig. 8a). I expressed the fusion protein in 
bacteria. It was partially soluble (Fig. 8b) so I used the GST tag for protein purification on 
glutathione agarose beads. I was able to achieve good purity after GST purification, only 
some shorter, partially degraded fusion proteins copurified with the full length GST-SRSF5 
(Fig. 8b).  
After the purification I encountered 
problems with protein precipitation at 
higher concentration, so I performed a 
thermofluor measurement to find an 
optimal buffer for storage of purified 
GST-SRSF5 (Fig. 8c). I used the R and Q 
proteins because they differed by charge 
to see if each of the proteins needs 
unique conditions. I tested a panel of 
buffering agents all at 100 mM 
concentration with varying pH. I found 
that GST-SRSF5 is stable in alkaline 
conditions (Table 4) and the best buffer 
was bicine. Both R and Q proteins were 
similarly stable. Based on the 
thermofluor data I formulated the final 
buffer for storage and in vitro RNA 
binding assay as 100 mM bicine buffer 
(pH 7.6) containing 300 mM NaCl, 0.5 
mM DTT and 10% glycerol. I decreased 
the pH from 8 to 7.6  because the in vitro assay was performed at low temperature and pH 
of the buffer prepared at room temperature increases at lower temperature. 
 
 
melting temperature °C 
buffers R  R  Q  Q 
NaCl 200 400 200 400 
Sodium acetate 4.5 37,4 34,6 38,4 34,9 
Sodium citrate 4.7 40,9 38,4 41,8 39,6 
Sodium acetate 5.0 45,3 42,9 45,4 43,3 
Potassium phosphate 5.0 47,1 35,5 47,9 46 
Sodium phosphate 5.5 51,9 49,1 51,3 40 
Sodium citrate 5.5 49,5 48,5 50,1 48,8 
Mes 5.8 50,3 48,9 50,6 48,2 
Potassium phosphate 6.0 51,3 50,1 51,6 50,2 
Mes 6.2 52,6 49,6 52,6 50,7 
Sodium phosphate 6.5 54,5 53 53,8 53,2 
Mes 6.5 54 52,1 53,6 51,9 
Potassium phosphate 7.0 54,2 53 53,8 52 
Hepes 7.0 54,2 52,4 54,4 53 
Sodium phosphate 7.5 54,8 53,7 54,8 53,1 
Ammonium acetate 7.3 54,5 52,9 54,8 53,1 
Tris 7.5 53,4 52,2 53,1 52 
Imidazole 8.0 53,1 51,8 53,5 51,9 
Hepes 8.0 54,9 53,2 54,8 52,7 
Tris 8.0 53,7 52,5 53,5 52,5 
Bicine 8.0 57,5 53,4 54,8 53 
Tris 8.5 54,8 53,1 54,9 53 
Bicine 9.0 55,7 53,8 56,1 53,5 
ddH2O 53,3 53,2 53,1 52,6 





Table 4:  Thermofluor measurement of melting 
temperatures of R and Q proteins in 24 different buffers 
containing either 200 or 400 mM NaCl. Tris pH 8.0 300 mM 
NaCl is the original buffer proteins were eluted into. 
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Quantification of SRSF5 interaction with RNA in vitro 
 From the range of available assays for RNA-protein interaction, I opted for fluorescence 
anisotropy measurement. It was performed in the lab of Richard Štefl (CEITEC, Brno) by 
Veronika Bačíková. In this experiment the solution of 5′ fluorescein-labeled 12 bp long RNA 
5′–UGACUCCACUGC–3′ consisting of two consecutive SRSF5 binding sites was titrated with 
purified GST-SRSF5(1–180) and increase in anisotropy was measured. The results were fitted, 
which allowed calculation of dissociation constant (Kd) of the RNA-protein interaction (Fig. 
9). 
Fig. 9: Fluorescence anisotropy measurement and calculated dissociation constants (Kd) for WT, R and Q 
interaction with RNA. 
 WT protein had the lowest Kd of 0.22 µM followed by R 0.45 µM and Q protein with 0.95 
µM. These results agree with the RIP measurements, where the mutant proteins bound less 
RNA than the WT. To control that the GST tag does not contribute to the binding of GST-
SRSF5 to RNA, interaction of purified GST alone with the RNA probe was measured and it 
was confirmed that it does not bind RNA. To check the specificity of interaction of GST-SRSF5 
with the designed probe containing SRSF5 binding sites, four other control RNA probes of 
identical length  were measured with the WT protein. Their Kd varied and in two cases it was 
low, probably due to resemblance of the probe to the SRSF5 binding site and in two other 
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cases their interaction with WT protein was weak. Negative control no.1 5′–
GGGGCCCCGUAA–3′ had the lowest affinity to SRSF5 with Kd of 5.27 µM. Negative control 
no.2 5′–GGGGCCCCCCCC–3′ had a Kd of 0.53 µM, negative control no.3 5′–GUAACCCCGGGG–
3′ 0.51 µM and negative control no.4 5′–AAUCUUAGUAAUC–3′ bound RNA again weakly 
with Kd of 1.81 µM. 
 
Influence of SRSF5 variants on splicing 
I was ultimately interested in how WT and mutant SRSF5 proteins function in pre-mRNA 
splicing. To test SRSF5 variants in a functional assay, I used a splicing reporter based on 
human fibronectin gene that was used in our lab previously (Hnilicova et al., 2011). It 
contains a part of the gene from exon 24 to exon 26, where exon 25 (called EDB or EDII) is 
alternatively spliced  and its inclusion is enhanced by SRSF5 binding directly to EDB exon and 
also to the intron downstream (White et al., 2008). 
I attempted to knockdown the endogenous SRSF5 in the cell lines so that the SRSF5-EGFP 
is the only version of the protein in the cell. In such situation even a recessive effect on 
splicing is unobscured by presence of the functional endogenous protein. I used siRNA 
targeted against 3′ UTR of human SRSF5, but the knockdown was inefficient (Fig. 10a,b). I 
detected a decrease in mRNA level of endogenous SRSF5, but it was not paralleled by a 
decrease in protein level. Amount of mouse SRSF5-EGFP mRNA was variable, and 
surprisingly EGFP-tagged proteins accumulated afer knockdown of the endogenous SRSF5. I 
also checked that expression of WT, R or Q proteins does not change expression of other SR 
proteins (Fig. 10a). Even though the knockdown was not successfull I performed the splicing 
assay to see if the mutant proteins have a dominant effect on splicing (Fig. 10c). The splicing 
reporter produces two variants of mRNA. A short variant without EDB exon and a long one 
with EDB included. I observed the ratio of the short to long variant by RT-PCR. There was 




Fig. 10: (a) The changes in protein levels after knockdown of endogenous SRSF5. The level of endogenous 
SRSF5 probed with m104 antibody, SRSF5-GFP probed with GFP antibody, GAPDH served as a loading control. 
NCsi denotes use of negative control siRNA and siSRSF5 denotes siRNA against SRSF5. Two biological 
experiments are shown. (b) SRSF5 mRNA levels after knockdown measured by qPCR, average of the above-
shown experiments is shown, error bars represent standard deviation. (c) DNA electrophoresis showing a 
ratio between short and long mRNA product from the fibronectin splicing reporter, below the denzitometric 
analysis in ImageJ, the band marked with asterisk is a hybrid between the short and long product and was 





In this work I studied the influence of mutations in acetylation site on function of an SR 
protein SRSF5. I established cell lines expressing WT and mutant SRSF5 tagged with EGFP 
and thoroughly assessed their phenotype. First the localization of the constructs in cells was 
in good agreement with literature (Shepard and Hertel, 2009). They accumulated in nuclear 
speckles, which is typical for splicing factors and especially SR proteins. The proteins 
rearranged rapidly in response to transcription inhibition and also during the cell cycle 
proving that availability of their substrate RNA is one of determinants of their localization 
within nucleus. 
Regarding the posttranslational modifications, I surprisingly detected the acetylation only 
in the wild type SRSF5 expressed from BAC (WTBAC) that served as a positive control and 
not in the wild type SRSF5 I cloned from cDNA. They differ mainly at RNA level because 
WTBAC contains its own promoter, UTRs and introns, whereas WT contains only the coding 
sequence. On the protein level they are very similar. Only WTBAC has longer linker sequence 
between SRSF5 and EGFP containing S-peptide and cleavage sites for TEV and Prescission 
proteases (Poser et al., 2008). It can be speculated that UTRs or introns are important for 
protein acetylation. But linking non-coding sequences in RNA to acetylation is problematic, 
because ε-N-acetylation of lysines occurs largely posttranslationally (unlike the N-terminal 
acetylation) and currently there is no known pathway that would transmit the information 
about presence of regulatory sequences in RNA onto the protein. Alternatively, acetylated 
lysine detected in WTBAC could be located in the linker sequence that is missing in the WT 
construct and does not reflect acetylation of SRSF5 itself. 
The third possibility may be the crosstalk between acetylation and phosphorylation, 
because I revealed that the WTBAC is almost three times more phosphorylated than WT and 
mutant proteins. So WT might not be phosphorylated enough to get acetylated. 
Phosphorylation might be crucial for interaction with HAT or other proteins in the HAT 
complex and therefore essential for the acetylation. But from the western blot it cannot be 
deduced if the same subpopulation of SRSF5 undergoes both acetylation and 
phosphorylation, if the modifications are mutually exclusive or completely independent. For 
SRSF2 there exists a crosstalk between modifications as mentioned already in the 
introduction, but it is rather indirect. Overexpression of SRSF2 acetyltransferase Tip60 
caused relocalization of SR protein kinases SRPK1 and SRPK2 from nucleus to cytoplasm and 
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thus decreased SRSF2 phosphorylation. The knockdown of Tip60 by siRNA had the opposite 
effect. On the other hand the SRSF2 deacetylase HDAC6 had no effect on SRSF2 kinases and 
SRSF5 phosphorylation (Edmond et al., 2011b). 
Next experiment where I assessed the phenotype of SRSF5 mutants was fluorescence 
recovery after photobleaching. I was not able to detect differential interaction of SRSF5 
proteins with RNA in vivo by this method, but I confirmed that all of them bind RNA because 
their recovery was faster after removal of binidng sites by transcription inhibition. 
The fact, that I did not detect a difference in localization or dynamics between WTBAC, 
which is more phosphorylated and acetylated and WT and mutants, which are not, shows 
that other factors than posttranslational modifications are more significant for SRSF5 
localization and dynamics. It was quite surprising in case of phosphorylation, because it is 
well established that it regulates SR protein localization (Misteli et al., 1998). The 
phosphorylated form should be nucleoplasmic and participate in splicing. So theoretically an 
increase in EGFP signal in nucleoplasm should have been detected in WTBAC, but a subtle 
change might have been neglected. The hypophosphorylated form of SR proteins tends to 
accumulate in speckles and also in cytoplasm, but such a pattern of EGFP signal was not 
observed in WT, R or Q cell lines. 
The major hypothesis tested in this work was how efficiently do the SRSF5 proteins with 
mutated acetylation site (K167) bind RNA. I was working with wild type protein that had a 
positively charged lysine at position 167. This lysine was not acetylated in the cells (Fig. 5). I 
also assumed that proteins isolated from bacteria for in vitro assay did not carry any 
posttranslational modifications. Similar to the wild type was the R mutant with arginine 
instead of lysine at position 167. More dissimilar was the second Q mutant with lysine 
switched for glutamine, which lacked the positive charge and mimicked acetylated lysine in 
the experiments. 
In the RNA immunoprecipitation experiment the three proteins were tested in their 
ability to pull down SRSF5 mRNA from the cell lysates. The mutants immunoprecipitated one 
third of the RNA pulled down by WT protein. The R mutant pulled down slightly more RNA 
than Q, but due to big variance of R values it is hard to conclude more. The fact that 
substitution K167R changed RNA binding properties similarly as the K167Q was unexpected 
because WT and R shared the positive charge at amino acid 167. This residue very probably  
plays a role in RNA-protein interaction, because any change at this position leads to 
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decreased RNA binding. This is further supported by analysis of Q mutant that interacted 
with RNA in vitro four times less efficiently than WT. 
The in vitro RNA binding assay represented a simple system, where the number of 
variables was minimized. In these conditions the WT protein showed again the strongest 
binding to RNA with Kd= 0.22 µM followed by R with Kd= 0.45 µM and Q with Kd= 0.95 µM. 
This result confirmed the RIP data. From the Kd values it can be deduced that the positive 
charge at position 167 in vitro improves RNA binding. It agrees with the most 
straightforward model where positively charged amino acid residues interact with negatively 
charged phosphates in RNA. As mentioned in the introduction it is not always this way, but 
in case of SRSF5 acetylation probably decreases affinity to RNA.  
None of the mutants failed completely to bind RNA which suggests that we should not 
think about acetylation as an inhibitor, but rather a modulator of RNA binding, which 
optimizes strength of the interaction, because the strongest ineraction of protein with RNA 
does not necessarily mean the best. Often weaker interaction is preferred, because not only 
binding, but also dissociation from the substrate is crucial for the reaction to proceed. 
Acetylation might be the decisive factor in alternative splicing events, which are susceptible 
to regulation and can easily come to different results. 
The lower affinity of mutant proteins to RNA was not revealed in vivo by their different 
localisation or faster recovery in FRAP. The reason why the expected difference is not 
detected in vivo is probably caused by different conditions of RNA-protein interaction in vitro 
and in vivo, where it occurs in huge ribonucleoprotein particles (RNPs). RNA binding depends 
on a lot more macromolecular interactions and lower affinity to RNA is balanced by 
involvement of other protein-protein interactions of unreduced strength. So the major 
determinant of localisation or dynamics of SRSF5 in vivo is most likely the RS domain, which 
is responsible for most protein-protein interactions and outweighs the influence of RNA 
binding by RRM domain. 
The fundamental question is not how acetylation influences binding of a protein to RNA, 
but how the altered RNA binding changes functioning of the protein. Therefore I decided to 
compare SRSF5 proteins in their influence on alternative splicing. Because the binding of SR 
proteins to splicing enhancer elements is at the core of their function, the assumption was 
that if the SR protein cannot bind to enhancer element, the exon in question should be more 
skipped. Such effect could not manifest itself on the background of functional endogenous 
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protein so I had to knock it down. Unfortunately the knockdown was not successfull and I 
saw only decrease in mRNA level, but the amount of endogenous human protein remained 
unchanged. In this experiment I observed an unexpected phenomenon. The decrease of 
mRNA of endogenous SRSF5 caused increase in expression of exogeous mouse protein. So 
there must be a mechanism that increases the stability or translation of exogenous SRSF5. 
SR proteins are known to have an intricate system of maintaining the level of their RNA 
present in cells by nonsense-mediated decay and clearly their regulation is even more 
complicated with additional mechanism at protein level documented here. This is not so 
surprising, because it is known that SR proteins also play a role in translation regulation. 
The next step in the research of SRSF5 acetylation would be to abandon the mutants and 
study the acetylation of SRSF5 directly. One would need to know which HAT acetylates and 
which HDAC deacetylates SRSF5. It would enable two in principle similar experiments. SRSF5 
could be acetylated in vitro and RNA binding assay in vitro could be repeated,  which would 
alow direct comparison of RNA binding between acetylated and non-acetylated form of the 
protein. Second, by overexpression or knockdown of those enzymes one could regulate 
SRSF5 acetylation and observe how the properties of protein are changing in vivo. HAT and 
HDAC of SRSF2 were mapped, as mentioned previously. It is Tip60 and HDAC6 (Edmond et 
al., 2011b). Those would be first candidates for SRSF5 too, but it needs experimental 
validation.  
This study could benefit from employment of mass spectrometry in several control 
experiments. There is a possibility that under normal conditions only small portion of protein 
is acetylated and phosphorylated, but this subpopulation gave the positive signal on western 
blot, however it is negligible when we observe the whole population of SRSF5 in cells. This 
would explain the lack of difference between mutants and WTBAC in localization and 
dynamics. This might be a concern for acetylation, which was hard to detect, but that is 
obviously influenced mostly by quality of antibody used. The ratio of acetylated to 
nonacetylated SRSF5 in cells can be determined only by mass spectrometry. This is not the 
only interesting question. We can ask also how this ratio changes in various conditions and 
by certain treatments. If high ratio of SRSF5 was acetylated, it would suggest that it has 
some functional significance. If little SRSF5 was acetylated or if the acetylation did not 
change in any condition, one would speculate that it has no functional significance and 
SRSF5 gets acetylated because some HAT evolved to acetylate similar epitope on a different 
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protein and acetylation of SRSF5 is only noise in the cellular acetylome. This might be a more 
general concern. The number of detected acetylations is huge and most of them still await 
confirmation in some functional study. Though the functional studies carried out so far 
confirmed that acetylation has a function in protein regulation, e.g., the metabolic enzymes 
(Zhao et al., 2010). However it can be  caused by bias towards publishing positive results. 
The high-throughput acetylation mass spectrometry data (Choudhary et al., 2009) also 
require validation. It has to be checked by mass spectrometry analysis of 
immunoprecipitated WTBAC protein that K167 is indeed acetylated. Additional acetylation 
sites might yet be discovered, because possibly some weak acetylation signal even in the R 





I confirmed the hypothesis that the amino acid side chain at acetylation site (K167) in 
SRSF5 RRM2 is important for RNA binding. The mutant with lysine replaced by arginine 
bound RNA with affinity lowered to 36% in vivo or to one half in vitro compared with wild 
type according to two alternative RNA-protein interaction assays. So a conservative 
substitution preserving a positive charge at position 167 reduced RNA binding. The 
acetylation-mimicking mutant had even more decreased RNA affinity. To 30% in vivo or one 
quarter in vitro according to the two assays. This shows the importance of positive charge at 
position 167 for high-affinity RNA binding and suggests that acetylation could reduce SRSF5 
binding to RNA. 
Reduced binding of mutants to RNA did not manifest in their other properties like 
subcellular localization and dynamics and they were very probably functional. It remains to 
be tested if the reduced ability of mutant proteins to bind RNA influences pre-mRNA splicing 
and other functions of SRSF5. In the future, the direct effect of SRSF5 acetylation on RNA 
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